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1. Introduction 
The ear is responsible for the perception of sound and the sense of balance. In 2015, the 
WHO estimated that worldwide 360 million people (over 5 % of the population) are suffering 
from disabling hearing loss, meaning a loss of 40 or 30 dB in the better hearing ear in adults 
and children respectively (1). In the USA 15 % of the population over 18 reported at least 
minor changes in hearing capacities (classification from “a little bit of trouble hearing” to 
“deaf”) (2). 
Hearing loss can have several causes: The loss before or soon after the birth of a child is 
one of the most frequent birth defects since 0.1 to 0.3 % of all neonates are born with 
congenital hearing loss (3,4). Nevertheless, hearing impairment nowadays can also be related 
to the certain employments of people: It has been reported that especially professional soldiers 
often suffer from hearing loss, tinnitus or other noise-related comorbidities following their 
service in the armed forces (5–7). 
Additionally, a lot of employees in the manufacturing sector suffer from occupationally 
induced hearing loss. In 2010, about 16 million people have been working in the 
manufacturing sector in the USA (8). Those 16 million people have reported 42 700 cases of 
nonfatal occupational illness in 2013, therein - representing the majority - 13 400 cases of 
hearing loss in 2013 (9). That means that nearly one third of the reported illnesses in the 
manufacturing sector is related to hearing loss. 
Importantly, hearing impairment can not only be related to the working situation but also 
to free time activities. The WHO states that 1.1 billion people have a high risk to suffer from 
hearing loss in the future due to excessive consumption of loud music in their free time, 
referred to as “recreational noise” (10). The use of audio devices or the attendance in a night 
club can lead to high noise levels over 85 dB that can damage the inner ear. E.g., the 
attendance to one single rock/pop concert with an average of 98.5 dBA resulted in a threshold 
shift of 10 dB or greater in 33.3 % of the examined persons in at least one ear compared to the 
data collected before the concert (11). 
The treatment of diseases of the inner ear remains a challenging topic: People from all 
over the world are affected by hearing loss, tinnitus or other diseases related to inner ear 
disorders. The impact on the personal lives of patients is tremendous: They might suffer from 
social exclusion which could lead to psychological, educational and economic problems. 
Furthermore, the patients might experience violence due to stigmatization or prejudices 
regarding this invisible illness (12). 
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Despite the personal challenge, the overall costs for the society should not be 
underestimated: Higher unemployment rates in combination with lower income of patients 
who receive insufficient treatment of their disorder are estimated to cause lost taxes of over 
18 billion US dollar annually in the USA (13). Especially the governments of developing 
countries sometimes seem to have difficulties providing the public with sufficient material 
and trained staff to treat hearing related illnesses. Therefore, children often receive 
appropriate treatment too late, e.g., in the LAUTECH Teaching Hospital (Osogbo, Nigeria), 
109 (48.9 %) cases of hearing impairment in children could have been prevented by an 
appropriate treatment (14). 
The examples cited above make it obvious why research on inner ear diseases remains a 
global challenge. To understand the underlying processes and find matching strategies to treat 
and help people whose daily lives are strongly affected by inner ear diseases will be a major 
topic in the upcoming years. 
Before describing current strategies to deliver drugs to the inner ear (section 1.2.), a brief 
introduction of the anatomy and physiology of the ear will be given in the following chapter. 
 
1.1. Anatomy and Physiology of the Ear 
The ear is divided into three main parts: the outer, the middle and the inner ear 
(Figure 1.1.). The outer ear consists of the auricle which is the visible part of the ear and the 
2.5 cm long ear canal that connects the outer ear with the tympanic membrane, also called ear 
drum (15). 
The middle ear is limited by the tympanic membrane which is connected to the malleus, 
the incus and the stapes, the tiny chained up ossicles in the tympanic cavity. The stapes at the 
end of the ossicular chain stays in connection with the oval window. The air filled tympanic 
cavity has a volume of 1 to 2 cm3 and is connected via the Eustachian tube with the oral 
cavity. Via this tube differences in pressure between the outer and the middle ear are 
compensated. 
The middle ear is connected to the inner ear via the round window membrane and the 
oval window membrane. Those are two semi-permeable membranes through the petrous bone 
which surrounds the inner ear. 
The inner ear consists of the cochlea where sound perception takes place and the 
vestibular system which is involved in the process to maintain the balance. 
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Figure 1.1. Anatomy of the ear: division into the outer (Auricle, Ear Canal, Tympanic 
membrane), the middle (Tympanic cavity, Ossicles, Eustachian tube) and the inner ear 
(Cochlea, Vestibular system), adapted from (16). 
 
The cochlea has the form of a snail and consists of three fluid filled canals with a length 
of 31 to 37 mm coiled up in the cochlea (16,17): scala tympani and scala vestibuli are filled 
with perilymph which has a composition similar to other extracellular fluids whereas the scala 
media situated between the two other scalae is filled with endolymph (Figure 1.2.a). The latter 
has an unusual composition with a high concentration of potassium ions of 150 mM leading 
to a high potential in the endolymphatic fluid. The scalae tympani and vestibuli are connected 
at the apex of the cochlea via the helicotrema and have a volume of 70 µL in humans and 
2.78 µl in gerbils which in both species is nearly ten times higher than the volume of the 
endolymphatic space (Table 1.1.). 
To separate the three scalae from each other there are two membranes in the inner ear: 
Reissner’s membrane between scala vestibuli and media as well as the basilar membrane 
between scala media and tympani (Figure 1.2.b). In the middle, the organ of Corti is situated 
in the scala media. The highly specialized inner and outer hair cells situated on the basilar 
membrane of the organ of Corti (Figure 1.2.c) are responsible for the translation of 
mechanical waves into electrical signals leading to the perception of sound in the brain (16). 
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Figure 1.2. Anatomy of the cochlea: Section through the cochlea: a) cochlea with three coiled 
up fluid filled spaces: scala vestibuli, media and tympani; b) zoom into the scala media with 
the Organ of Corti – the organ containing the sensory cells; c) zoom into the Organ of Corti 
with three rows of outer hair cells and one row of inner hair cells, adapted from (16). 
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Table 1.1. Characteristics of fluids inside the cochlea: Perilymph and Endolymph in humans, 
adapted from (18,19). 
 Perilymph Endolymph 
Volume, µL 70 8 
Volume (gerbil), µL 2.78 0.38 
Na+, mM 160 1 
K+, mM 4-5 150 
Cl-, mM 120 130 
H2CO3, mM 20 30 
Ca2+, mM 1.2 0.02 
Glucose, mM 4 0.5 
Proteins, g L-1 1 0.15 
pH 7.4 7.4 
Osmolality, mOsm kg-1 290 315 
Potential, mV 0 +80 
 
The vestibular system consists of the three semicircular canals as well as the vestibule 
which comprises of the utricle and saccule. It stays in contact with the fluids of the cochlea. 
That is why the inner ear can also be divided into the bony labyrinth, filled with perilymph, 
and the membranous labyrinth, filled with endolymph (20,21) (Figure 1.3.). The perilymph of 
the bony labyrinth stays in contact with the cerebrospinal fluid and surrounds the membranous 
labyrinth (22). Nevertheless, the flow of the inner ear fluids is very low which means that the 
local conditions in the vestibular system and the cochlea are maintained locally in each 
compartment of the two labyrinths (23). 
Part of the membranous labyrinth of the vestibular system are the semicircular canals: the 
superior, the horizontal and the posterior canal. They are arranged at right angles to each other 
and open out into correspondent ampullae leading to the utricle (Figure 1.3. on the left hand 
side). The ampullae, the utricle and the saccule contain specialized hair cells detecting 
movement of the head: the macula is situated in the utricle and saccule whereas the crista 
ampullaris is situated in the ampullae (21).  
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Figure 1.3. Anatomy of the inner ear: The fluids of the cochlea (right) stay in contact with the 
fluids of the vestibular system (left). The bony labyrinth with the Perilymph (light grey) 
surrounds the membranous labyrinth containing Endolymph (dark grey), adapted from (22). 
 
This system reacts very sensitive to potentially toxic changes and, though, is protected by 
several barrier systems described in the following chapter. 
 
1.1.1. Barriers of the Inner Ear 
The highly sensitive inner ear is protected via three different barriers: The Blood-cochlea 
barrier, the tympanic membrane as well as the oval and the round window (18). 
The blood-cochlea barrier, also called the blood-perilymph barrier, is similar to the 
blood-brain barrier: Diffusion of drugs from the systemic blood circulation into the inner ear 
is limited due to the special composition of the capillary endothelium of the blood vessels. It 
is blocking the entrance of drugs from blood stream into the cochlea via tight junctions 
without fenestrations (24–26). Furthermore, p-glycoprotein (p-gp) as well as multidrug 
resistance protein 1 (MRP1) has been detected in the inner ear indicating that it is also 
protected by efflux pumps (27,28). The impact on clinical results is important, e.g., 
dexamethasone administered i.v. resulted in significant lower cochlear concentrations 
compared to drug administered intratympanically (29). Nevertheless, it seems that drugs can 
enter the inner ear depending on their chemical characteristics. Small lipophilic drugs can 
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enter the perilymph more easily than big hydrophilic, charged or protein binding drugs (25). 
Finally, positively charged drugs are less likely to enter the endolymphatic space from the 
perilymph because of the electrical gradient (Table 1.1.) (25). Importantly, various conditions 
can disturb the blood-cochlea barrier, e.g. noise exposure, inflammation, the administration of 
diuretics or several osmotic agents (18).  
The tympanic membrane (Figure 1.1.) protects the middle ear from toxic substances 
entering through the ear canal of the outer ear and has an area of 85 to 90 mm2. It consists of 
an outer epidermal layer, followed by a fibrous layer as well as an inner mucosal layer and 
has an almost oval and conical shape (15,30). During intratympanic injection this membrane 
is damaged.  
 
Figure 1.4. Barriers of the inner ear: 3D-reconstruction of a human inner ear. The round 
window membrane (RWM) stays in contact with the scala tympani whereas the oval window 
membrane (OWM) is connected to the scala vestibuli, adapted from (31). 
 
The round and the oval window connect the middle ear with the cochlea which is 
surrounded by the petrous bone (Figure 1.4.). Unfortunately, drug delivery to the inner ear 
through the petrous bone – one of the densest bones in the body – seems to be limited in 
humans. Importantly, drug delivery through this bone seems to be overestimated in animal 
experiments because the bone in animals is very thin compared to the bone in humans (32). 
Both, the round and oval window membrane, are not only barriers but also a potential 
target for local drug delivery. The round window is connected to the scala tympani at the 
basal turn of the cochlea. It consists of three layers, an outer epithelium with a single layer of 
cells, a middle layer of connective tissue containing fibroblasts, blood vessels, collagen and 
Scala tympani 
Oval window membrane 
Scala vestibuli 
Scala media 
Round window membrane 
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elastic fibers as well as an inner layer consisting of squamous epithelium (18). The round 
window niche has an opening width of about 0.5 to 3 mm, the membrane has a thickness of 
about 50 - 100 µm in humans compared to 10 to 14 µm in rodents (18,33,34). The ovoid 
surface of the round window is around 2.2 mm2 in humans compared to 1 mm2 in rodents and 
can have various shapes (18,34). Unfortunately, the round window membrane is often 
plugged by a pseudomembrane, a fat plug or fibrous tissue which makes the quantification of 
drug delivery quite challenging. From 85 patients, 22 % had obstructions in both ears whereas 
only 56 % of the examined patients had no obstacle in both ears at the round window niche 
(35). Additionally, the transport of a drug through the round window membrane depends 
highly on the size, concentration, solubility, electrical charge and uptake mechanism of the 
drug (18) which makes the development of an appropriate drug delivery system very 
challenging and time consuming. 
The second membrane connecting the middle with the inner ear is the oval window 
which stays in contact with the perilymph of the scala vestibuli at the base of the stapes. The 
stapes’ footplate is attached to the oval window by the annular ligament and has a normal 
thickness of 0.3 to 0.5 mm in humans (33). The length of the footplate has been measured to 
be 2.5 to 3.36 mm compared to a width of 0.7 to 1.66 mm (36). It has been calculated that the 
surface area of the stapes footplate is about 3.97 mm2 (36). In the past, clinicians thought that 
the drug enters the inner ear mainly through the round window membrane. Recent studies 
indicate that drugs can also enter the inner ear via the stapes footplate (37): It has been 
calculated that the ionic marker trimethylphenylammonium (TMPA) enters the inner ear 
mainly through the round window membrane, but, importantly, one third of the drug enters 
through the oval window membrane (31). 
Those barriers protect the inner ear, more precisely the inner ear hair cells. This 
mechanoreceptor cells are responsible for the auditory perception that will be described in the 
following chapter. 
 
1.1.2. Auditory perception 
The sound that is processed in the inner ear and detected in the brain depends on the 
characteristics of the sound waves arriving at the outer ear. Sound waves can be described 
regarding the amplitude (or intensity), the wavelength, the frequency and the phase (16). 
Briefly, the sound wave is collected by the auricle, passes the ear canal where it is amplified 
and, subsequently, causes movement of the tympanic membrane (15). This movement is 
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converted into mechanical vibrations that are – again – amplified and transferred via the 
ossicles to the oval window membrane. The movement of the stapes is converted at the oval 
window into a pressure wave which is spread throughout the fluid filled cochlea - from the 
oval window of the scala vestibuli via the apex of the cochlea to the round window of the 
scala tympani. 
Inside the cochlea, the sound wave causes vibration of the basilar and the tectorial 
membrane. Depending on the frequency of the sound wave, especially the cells in the 
corresponding area of the cochlea are stimulated: Human beings can detect low frequencies 
from approximately 20 Hz at the apex until high frequencies of 20 000 Hz at the base of the 
cochlea (Figure 1.5.) (15). Mongolian gerbils have a hearing frequency range of 100 to 
60 000 Hz (38). In humans, the ability to detect high frequencies is typically decreasing with 
age. 
Figure 1.5. Perception of sound inside the cochlea depending on the frequency of the sound 
wave in humans: High frequencies stimulate the hair cells at the base whereas low frequencies 
vibrate the hair cells at the apex of the cochlea, adapted from (39). 
 
The difference between the vibration of the basilar and the tectorial membrane causes a 
shearing force. Subsequently, this mechanical signal is translated into an electrical signal in 
the specialized outer and inner hair cells of the organ of Corti: The stereocilia situated on top 
of the hair cells vibrates depending on the mechanical wave. This vibration causes the hair 
cells to depolarize and repolarize by opening of potassium and calcium channels. The sound is 
amplified by the outer hair cells which leads to vibration and release of transmitters from the 
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inner hair cells that activate receptors in the nerve leading to the brain. Subsequently, this 
signal is transferred to the brain where the sound is perceived (16,40). 
Along with this first perceptional system situated in the cochlea, the second main system 
in the inner ear, the vestibular system, is responsible for the equilibrioception and will be 
described in the following chapter. 
 
1.1.3. Sense of balance 
The semicircular canals and the vestibule of the inner ear (Figure 1.3.) are part of the 
system maintaining the balance of the body. Not only the inner ear is involved in this process 
but also the eyes, muscles, the brainstem, the cerebellum and the cortex (21,41). In this 
context, the inner ear hair cells play a major role in translating the movement of the head into 
electrical signals which can be interpreted by superordinate systems. 
Therefore, two types of hair cell containing membranes exist in the vestibular system: the 
macula, also called otolitic organ, and the crista ampullaris. The mechanosensitive hair cells 
inside those membranes consist of a kinocilium and 70 to 100 stereocilia (21). 
Macula membranes exist inside the utricle and the sacculus of the vestibule and are 
responsible for the detection of linear acceleration and head tilt (41). Those membranes 
contain not only hair cells but also “heavy” calcium carbonate crystals, so called otoliths. 
They are embedded in the otolitic membrane which covers the gelatinous layer containing the 
hair cells. When the head is leaned forwards or moved linearly these crystals are displaced. 
They cause a shearing force between the otolitic membrane and the macular surface leading to 
a bending of the hair cells followed by an electrical signal which can be detected in the brain 
(21). 
The crista ampullaris inside the ampullae at the end of the semicircular canals detect 
angular acceleration. Since the three semicircular canals are arranged orthogonal to one 
another the hair cells in each ampulla can detect movement in the three dimensions (22). 
Therefore, the hair cells are embedded into a gelatinous structure, the cupula, similar to the 
macula. In contrast to the otolitic structure of the macula, the hair cells of the crista ampullaris 
are bent due to the movement of the endolymph of the membranous labyrinth and contain no 
calcium carbonate crystals. When the head is moved the endolymph inside the semicircular 
canals flows in the opposite direction of the movement causing the bending of the cupula. In 
consequence, the hair cells are bent and stimulated (Figure 1.6.). A continued uniform 
movement of the head results in a return of the cupula to the original position, stopping the 
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motion results in a bending of the cupula in the opposite direction with correspondent hair cell 
polarization (21). The signals from the vestibular system are transduced via the nerve to the 
brain where head and eye movement are matched to maintain the balance of the body (22). 
 
 
Figure 1.6. Function of the crista ampullaris: Rotation of the head causes endolymph flow 
inside membranous labyrinth in the opposite direction. The cupula waves depending on the 
flow leading to a stimulation of the hair cells (21). 
 
Damage in the cascade of auditory perception or the sense of balance in only one step 
can lead to inner ear disorders that are described in the next chapter. 
 
1.2. Diseases of the inner ear 
Current strategies to treat inner ear diseases aim at the treatment of Noise Induced and 
Sudden Sensorineural Hearing Loss (NIHL and SSHL respectively), of Autoimmune Inner 
Ear Disease (AIED), Tinnitus or Meniere’s Disease and the protection of the inner ear, e.g., 
during aminoglycoside or anti-cancer therapy. In this introduction a major focus will be on 
Hearing Loss. Additionally, a short overview on other illnesses will be given here. 
Autoimmune Inner Ear Disease causes bilateral, generally asymmetric, progressive or 
fluctuating hearing loss that is often combined with a systemic autoimmune disease of the 
patient as well as vestibular symptoms and responds to immunosuppressive therapy (42,43). 
Researchers assume that the etiology of the disease includes inflammation, vascular and 
cochlear tissue damage (e.g., Stria vascularis, Spiral ganglion, Organ of Corti) due to a 
disproportionate Th1 immune response (42). Therapy includes systemic and intratympanic 
administration of corticosteroids for a prolonged period. Sometimes other immunosuppressive 
agents like methotrexate or cyclophosphamide seem to be beneficial for the patient by 
reducing the dose of steroids. Recent research focuses on fusion proteins and monoclonal 
Cupula 
Head 
movement 
Endolymph 
movement 
Hair cell 
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antibodies to block the inflammatory reaction. A second promising approach might be the 
application of stem cell and gene therapy to repair damaged inner ear tissues (43). 
Tinnitus is defined as the perception of sound without an external acoustic stimulation 
(44,45). The cause of the disease is unclear, researchers discuss not only a peripheral but also 
a central neural origin (46). This disease can occur following to excessive noise exposure or 
during the normal process of aging and can be associated with additional symptoms like 
hearing loss, sleep disturbance, hearing loss, anxiety and depression (45). Therapy aims at 
interrupting or masking the “phantom” sound via sound therapy (47) but also includes an 
appropriate treatment of the additional symptoms. This treatment might involve supply with 
hearing aids, education, psychological support, relaxation and cognitive behavioral therapy 
for the patient (44,45). Research on drugs that might be promising for the treatment of 
Tinnitus focuses on corticosteroids, e.g., dexamethasone, local anesthetics, e.g., lidocaine, and 
n-Methyl-d-aspartate receptor antagonists (18). 
Patients suffering from Meniere’s disease report intermittently occurring episodes of 
vertigo, often associated with hearing loss, tinnitus or an aural pressure (48). This illness has 
an enormous impact on patient’s lives and researchers still discuss about its origin. 
Autoimmune reactions or viral infections might cause endolymphatic hydrops as well as 
fibrosis and tissue degeneration leading to the major symptoms of Meniere’s disease (48). The 
treatment with intratympanic Aminoglycoside antibiotics, e.g., gentamicin, seems to reduce 
vertigo but increases the risk to suffer from hearing loss (49). Also transtympanic injection of 
steroids seems to have a beneficial effect on vertigo attacks but further studies should be 
performed to proof those promising results (50). 
Otoprotective actions should be taken to prevent hearing loss due to Cisplatin or 
Aminoglycoside related toxicity. Both groups of drugs cause similar damage to the inner ear 
hair cells. Mainly outer hair cells inside the cochlea are degraded, while the damage is 
increasing from the apex to the base of the cochlea (51). Therefore, an increasing hearing 
impairment at the correspondent frequencies can be observed. Hearing Loss due to Cisplatin 
administration during anti-cancer therapy is not only age- (very young and the elder patients 
are more affected) but also dose-dependent (25): Administration of the ototoxic drug via an 
osmotic pump with concentrations from 0 to 300 µg/mL respectively resulted in greater and 
faster hearing loss when a higher concentration is administered (52). Spiral ganglion cells can 
also be affected. Additionally to this hearing loss, during aminoglycoside administration 
vestibular toxicity can be observed. The mechanism behind seems to be an excessive level of 
reactive oxygen species damaging especially outer hair cells (25). Local administration of 
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antioxidants seems to be promising but systemically administered methionine or sodium 
thiosulfate decreases the effectiveness of the cisplatin therapy (25). Furthermore, the use of 
cytoprotective agents, e.g., amifostine, has not been proven to prevent hearing loss due to 
cisplatin therapy in children (53). During aminoglycoside therapy, otoprotection can be 
achieved by the administration of antioxidants as well as steroids (25). 
Hearing loss can be related to all of the inner ear illnesses described above and, thus, will 
be discussed in detail in the following chapter.  
 
1.2.1. Hearing Loss 
Especially when it occurs suddenly, hearing loss is a frightening disorder for the patient. 
In addition to the hearing loss patients may report tinnitus (“ringing” of the ears), dizziness or 
fullness of the ear (54). 
According to the World Health Organization there are five grades of hearing impairment 
(Table 1.2.): no, slight, moderate, severe and profound impairment (Grades 0 to 4 
respectively). Following this classification, disabling hearing impairment occurs when the 
patient has at least a hearing loss of Grade 2. This moderate impairment with a loss of 41 dB 
or more on the better hearing ear means that words can still be understood and repeated at 1 m 
distance with a raised voice (55). 
 
Table 1.2. Hearing impairment according to the definition of the WHO: with a grade 
exceeding grade 1 hearing aides are recommended, adapted from (55). 
Grade Threshold shift of the better ear, dB Effect 
0 25 or better No/slight problems, even whispers are heard. 
1 26 to 40 Words spoken in 1 m distance with 
normal voice can be heard and repeated. 
2 41 to 60 Words spoken in 1 m distance with raised 
voice can be heard and repeated. 
3 61 to 80 Some words can be heard when shouted. 
4 81 or greater No words can be heard and understood 
even when shouted. 
 
The causes of hearing loss are various. In general, they can be classified as congenital or 
acquired (1). Congenital hearing loss refers to causes occurring during or shortly after birth, 
e.g., rubella, toxoplasmosis or other infections of the mother as well as treatment with 
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inappropriate drugs during pregnancy, asphyxia and low weight of the newborn (56). 
Importantly, genetic factors also play a major role in 25 % of the cases, over 400 gene related 
syndromes have been identified (4,56). Unfortunately, in 57 % of the cases the cause of 
congenital hearing loss still remains unknown (4). 
Acquired hearing loss refers to cases occurring at every age of the patient and can 
develop suddenly or over a long period. Hearing loss can develop due to infections, e.g. 
meningitis, measles, mumps or otitis media, as well as traumata of the head or the ear 
following an accident or surgery (1,55,57). Other causes can be autoimmune diseases, e.g. 
systemic lupus erythematosus, tumor growth and treatment, neurologic diseases, e.g. Multiple 
sclerosis, or vascular events (58–61). Additionally, certain drugs can have a toxic effect on the 
ear, e.g. aminoglycoside antibiotics as well as several chemotherapeutic agents and anti-
malaria drugs (51,62,63). Importantly, also acute or long term noise exposure can cause noise-
induced hearing loss (NIHL), e.g. recreational noise during a sport event or from a MP3-
Player and noise from machines or explosions. Also, a certain degree of hearing loss is age-
related (64) and can be considered as a normal process: It was estimated that 30 % of the men 
and 20 % of the women over 70 suffer from hearing loss (threshold shift of at least 30 dB) in 
Europe (65). Frequently, patients are also diagnosed with hearing loss due to excessive ear 
wax stuck in the ear canal (66). Nevertheless, only in 7 to 45 % of patients with Sudden 
Sensorineural Hearing Loss (SSNHL with a threshold shift of at least 30 dB over three 
continuous frequencies during 72 h) the cause can be identified, a major part of cases remains 
idiopathic (57). 
 
Table 1.3. Types of hearing loss with the concerned region, according to (15). 
Type of hearing loss Concerned region 
Conductive Disease of external and/or middle ear 
Sensorineural Disease of the cochlea and/or nerve 
Mixed Combination of conductive and sensorineural 
Central Disease of the auditory pathway higher than the auditory nerve 
 
Depending on the region, there are several types of hearing loss (Table 1.3.) (15). 
Conductive loss occurs when the stiffness of the outer or middle ear is changed, e.g. when the 
ear canal is stuck with ear wax or in case that the ossicular chain is damaged because of 
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otosclerosis (67). Sensorineural hearing loss (SNHL) occurs when the cochlea or the nerve is 
damaged, e.g. this is the case when hair cells of the organ of Corti are damaged due to 
gentamicin administration (37). A combination of conductive and sensorineural is a so called 
mixed hearing loss. When the auditory system is damaged in higher regions than the auditory 
nerve a central hearing loss occurs. 
Nevertheless, the cause of hearing loss is unknown in most of the cases and therapy still 
remains challenging. Ongoing research on different strategies to treat hearing loss is discussed 
in the following chapter. 
 
1.3. Drug delivery to the inner ear 
Current strategies used in clinic focus mainly at treating Sudden Sensorineural Hearing 
Loss and autoimmune diseases as well as at a protection of the inner ear (25). Besides the 
strategy of providing the patient with appropriate medical devices, e.g., hearing aids or 
cochlear implants to cure persistent hearing loss, different drug delivery tools are a major 
topic in research. 
Since the rate of spontaneous recovery from Sudden Sensorineural Hearing Loss is 
relatively high (32 to 65 %) and the etiology of Hearing Loss is not fully understood yet, 
clinicians discuss about the appropriate treatment of hearing loss. Nevertheless, in case that 
the cause is known, the patient should be treated accordingly (57,66). In the case of Idiopathic 
Hearing Loss, current therapeutic strategies often include systemic or local administration of 
steroids but also antivirals, diuretics, vasodilators, antioxidants, hyperbaric oxygen treatment, 
middle ear surgery and bedrest are used to treat hearing loss (57,66). 
Systemic drug delivery (described in section 1.3.1.) is still used to treat inner ear diseases 
but is progressively replaced by local drug delivery (described in section 1.3.2.) to avoid 
adverse events caused by high systemic blood concentrations of the drug. 
 
1.3.1. Systemic drug delivery 
Unfortunately, the systemic administration of both, steroids, optionally combined with 
antivirals, and vasodilators did not show a significant improvement in Cochrane Reviews 
(54,68,69). This may be partially due to insufficient patient numbers and inconsistent 
inclusion criteria or study designs. 
However, oral steroids may be useful in the treatment of sudden sensorineural hearing 
loss but their influence on hearing recovery remains uncertain. Only one of three studies 
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included in the Cochrane Review showed a significant effect of oral steroids on hearing 
recovery with a hearing improvement of 61 % compared to 32 % in the placebo/untreated 
group (70). In two other studies no improvement of hearing loss can be seen when oral 
steroids are administered (71,72). 
The systemic administration of antivirals to treat idiopathic sudden sensorineural hearing 
loss neither shows improvement: Two studies included in a Cochrane review showed no 
improvement when aciclovir was administered additionally to prednisolone (73,74). 
Accordingly, patients treated with valaciclovir in addition to prednisone, or aciclovir 
administered additionally to hydrocortisone, showed no hearing improvement (75,76). 
Nevertheless, animal studies support the assumption that an early treatment of patients with 
antivirals could be beneficial. Unfortunately, in clinical practice most patients present very 
late so the impact of the treatment with antivirals may be difficult to prove (54). 
The administration of vasodilators or vasoactive substances could be beneficial for the 
treatment of hearing loss but due to the small number of patients included in the studies the 
benefit remains unproven (68). A significant hearing improvement has been reported for 
patients receiving carbogen additionally to several other drugs compared to no inhalation of 
carbogen (77). In a study where patients received Prostglandin E1 additionally to 
hydrocortisone only the hearing in higher frequencies was improved (78). The hearing in 
lower frequencies was improved by the administration of low molecular weight Dextran with 
additional Naftidrofuryl (79). Those results are promising clinicians should be aware of 
potential side effects of drugs whose benefit for the patient is not yet approved in clinical 
practice (66). 
In addition to the unknown cause of the disease in most of the cases, during systemic 
administration of drugs side effects are more likely to occur. The patient often needs an 
elevated dose to enhance absorption of the drug into the inner ear to reach therapeutic drug 
concentrations. This is due to the barriers protecting the highly sensitive inner ear as described 
before (chapter 1.1.1. Barriers of the Inner Ear). Additionally, the small volume of the inner 
ear fluids and its complicated anatomical access make local drug delivery very difficult. 
Nevertheless, local drug delivery seems to be a promising approach to limit adverse 
events during the treatment of hearing loss and will be discussed in the following chapter. 
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1.3.2. Local drug delivery 
Local inner ear drug delivery has been the topic of several reviews in the last years 
(Table 1.4.). Most reviews concentrate on either intratympanic or intracochlear administration 
of drugs: El Kechai et al. recently published an interesting update focusing on intratympanic 
administration and in vivo studies (18), whereas Ayoob and Borenstein focused on 
intratympanic drug delivery (26). The review of Salt and Plontke deals with the 
pharmacokinetics of the inner ear (80). Salt also provides a program to simulate cochlear 
fluids of several species (81). 
 
Table 1.4. Reviews on inner ear drug delivery, adapted from (82). 
Main focus of the review Author Reference 
Overview on inner ear drug delivery systems Swan et al. 2008 (25) 
Pharmacokinetics of the inner ear Salt and Plontke, 2009 (80) 
Historical background, current strategies McCall et al., 2010 (83) 
Drug delivery using nanoparticles Pyykkö et al., 2011 (84) 
Drug delivery using micropumps Leary Pararas et al., 2012 (85) 
Intratympanic drug delivery Liu et al., 2013 (82) 
Intracochlear administration Ayoob and Borenstein, 2015 (26) 
Intratympanic administration, in vivo studies El Kechai et al., 2015 (18) 
 
The two major strategies to deliver drugs locally to the inner ear are intratympanic and 
intracochlear drug delivery. Depending on the intended treatment both systems have various 
benefits and drawbacks. 
During intratympanic delivery the drug is placed inside the tympanic cavity where the 
drug is absorbed mainly via the round but also by the oval window. The advantage of this 
strategy is the relatively save, usually ambulatory administration, often requiring no general 
anesthesia, allowing for short and mid-term drug delivery to the middle or inner ear. 
Unfortunately, the preparation might be washed away through the Eustachian tube or 
degraded rapidly and, though, often requires repeated application. These repetitions increase 
the risk of introducing pathogens into the inner ear. Additionally, the anatomy of the ear 
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varies from patient to patient leading to different drug concentrations in the inner ear. 
Depending on the characteristics of the drug, a gradient along the length of the cochlea can 
occur (18,25). 
Intracochlear delivery allows for the release of drugs directly inside the cochlea and 
requires a cochleostomy. The main advantage of this administration is the direct access to the 
inner ear ensuring a defined long term drug delivery during months or years bypassing 
inter-patient anatomical differences. Importantly, the characteristics of the drug only play a 
minor role since the drug is not obliged to pass the barriers protecting the inner ear. However, 
the patient has to stay in hospital during the treatment which is rather invasive and the 
surgeon risks to introduce pathogens during the operation (18,25). 
 
1.3.2.1. Intratympanic drug delivery 
Today, intratympanic administration of a drug loaded solution is commonly used in 
clinical practice. Therefore, the tympanic cavity is filled with the solution which is injected 
via the tympanic membrane using a thin needle. The outcome is promising: Patients suffering 
from Sudden Sensorineural Hearing Loss whose first line treatment with oral steroids failed 
could benefit from a treatment with intratympanic steroids which has led to a reduction in 
hearing thresholds (86). Other diseases of the inner ear might be treated accordingly using 
aminoglycosides, glutamate receptor antagonists, protease inhibitors, antioxidants or 
neurotrophins (25). 
Unfortunately, the drug solution is often eliminated very fast from the middle ear cavity. 
To enhance the residence time at the round window membrane, promising devices are the 
Silverstein MicroWick®, the Round Window µ-CathTM and the Round Window E-CathTM. 
Another strategy is to place biodegradable polymers loaded with either a drug solution or 
nanoparticulate systems inside the middle ear, e.g., close to the round window membrane 
(18,87). 
 
Medical devices 
MicroWick® 
The MicroWick® is a cylinder (dimensions 9 or 19 x 1 mm) consisting of polyvinyl 
acetate. It stays in contact with the round window membrane and passes through a perforation 
in the tympanic membrane. A drug solution (that can be administered dropwise into the ear 
canal of the outer ear by the patient himself) is absorbed by the polymer and, thus, transported 
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to the round window (25). The device is often used to treat vertigo occurring during 
Meniere’s disease with gentamicin (88), but also patients suffering from Sudden 
Sensorineural Hearing Loss can profit from a prolonged drug delivery: 26 patients receiving 
methylprednisolone during 10 days (after failure of the conventional therapy against hearing 
loss) had improved mean speech discrimination scores. The score recorded at 40, 55 and 
70 dB improved by 24.2 ± 8.7 % (89). Despite these promising results, the application of the 
MicroWick® might result in a permanent perforation of the tympanic membrane (82,83). 
Additionally, the risk of infection of the middle ear is increased due to the connection to the 
outer ear (83). The compliance of the patient is important because the drug solution is 
administered usually several times per day during weeks. 
 
µ-CathTM and E-CathTM 
The microcatheters can be used to deliver drugs intratympanically and via an 
intracochlear approach. They have two different canals: The first serves to infuse a solution, 
the other to withdraw fluids. The E-CathTM has a third canal that can be used to insert an 
electrode to control inner ear function during surgery (25). The tip of the microcatheter is 
inserted through a tunnel drilled into the temporal bone and fixed near the round window. 
This device has been used successfully to treat Sudden Sensorineural Hearing Loss (90). To 
facilitate the removal of plugs blocking the round window niche and the intratympanic 
injection of drug preparation, an otoendoscope has been developed that can visualize the 
middle ear during surgery. It has two canals: the first one serves removing mucosal adhesions, 
via the second one a drug solution can be injected into the middle ear (91). After treatment 
during several weeks, the catheter can be removed (83). Potential drawbacks are the risk of 
catheter dislocation or obstruction, the formation of granulation tissue and a potentially 
permanent perforation of the tympanic membrane (83). 
 
Polymeric matrices 
Hydrophilic polymers are widely used in research since the residence time of the 
formulation at the round window compared to intratympanically injected solutions is 
increased. These polymers can not only be administered in the form of solid sponges or discs 
but also as injectable in situ forming gels. The drug is released through degradation of the 
matrix, diffusion of the drug or a combination of both mechanisms (82). Thus, drug 
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concentration inside the cochlea seems to be more consistent, the concentration gradient along 
the scala tympani seems to decrease. 
 
Gelfoam® 
Gelfoam® is a compressed biodegradable sponge based on purified porcine gelatin which 
is used because of its hemostatic and fluid absorbing properties. Prior to the use as a drug 
delivery device, the polymer is soaked in drug solution. Promising results have been reported 
for the delivery of brain-derived neurotrophic factor (BDNF): Guinea pigs have been 
deafened and treated with a sponge that was loaded with BDNF and placed onto the round 
window. This treatment increases spiral ganglion cell survival in the basal turn of the cochlea 
after 2 and 4 weeks, thus, provides a protection to inner ear cells. Unfortunately, this effect in 
lower compared to studies working with an intracochlear approach (92). Silverstein et al. 
treated patients suffering from Meniere’s disease with a Gelfoam® sponge loaded with 
gentamicin solution. Vertigo was controlled in 75 % of the patients; hearing was preserved in 
90 % of the cases (93). 
 
SeprapackTM 
SeprapackTM is a bioresorbable device consisting of carboxymethyl cellulose and 
hyaluronic acid. Several studies evaluated the capacity of dexamethasone loaded SeprapackTM 
gels to reduce hearing loss due to trauma, e.g., during cochlear implantation (82). The 
administration of dexamethasone-loaded SeprapackTM before the implantation resulted in 
detectable drug concentrations inside the cochlea what was not the case when other types of 
delivery beads were applied. Dexamethasone protects residual hearing during cochlear 
implantation (94). In another study, it was confirmed that an administration of the 
dexamethasone-loaded device before the implantation resulted in increased hearing thresholds 
from 2 to 32 kHz. Importantly, protection increased with longer application time of the drug 
loaded device. Also, higher concentrations of dexamethasone applied onto the round window 
membrane resulted in better hearing protection in the second turn of the cochlea (95). 
 
Hydrogels 
Hydrogels can also be administered to the inner ear via intratympanic injection of the gel 
itself or in the form of an in situ forming gel. Various polymers have been tested to adjust 
drug delivery from the gels, e.g., gelatin, chitosan glycerophosphate, hyaluronic acid, alginate, 
siloxane, poloxamer 407 and collagen (25,82,83). 
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Chitosan, a non-toxic cationic polymer, has been used to deliver dexamethasone to the 
inner ear of mice. In vitro, the chitosan-glycerophosphate hydrogel released 92 % of the drug 
during 4 days. In vivo, dexamethasone has been detected during 5 days. Reversible hearing 
loss has been reported after surgery but mice recovered spontaneously after 10 days (96). 
Gelatin is not only administered as the solid Gelfoam® but also as a gel: The 
biodegradable polymer has been used to deliver the recombinant human insulin-like growth 
factor 1 (rhIGF-1) to prevent damage of the inner ear cells upon excessive noise exposure. 
Histological evaluation confirmed a higher survival of outer hair cells when the gel is applied 
onto the round window membrane (97). 
An interesting approach to prolong drug delivery is to use temperature-sensitive systems: 
The formulation can be injected intratympanically at room temperature as a liquid solution 
and forms a gel at body temperature (sol-gel-transition), e.g., on the round window 
membrane. Poloxamer has been used to provide prolonged dexamethasone release to the inner 
ear by forming an in situ forming gel. Concentration gradients along the scala tympani were 
lower compared to when injecting a solution. This can be partially due to a formation of the 
gel at the thin bone at the apex of the cochlea (which is more permeable in rodents than in 
humans) but can possibly related also to an extended release of the drug (98). This promising 
formulation is currently under clinical evaluation in Phase IIb to treat Meniere’s disease with 
a sustained release of dexamethasone (OTO-104, Otonomy) (18,99). 
Other candidates for clinical practice are two formulations based on hyaluronic acid to 
cure Noise Induced Hearing Loss and Tinnitus, administering dexamethasone and esketamine 
(AM-111 and AM-101 respectively, Auris Medical) (18). Additionally, a gelatin-based 
preparation releasing IGF-1 to cure Sudden Sensorineural Hearing Loss is clinically evaluated 
(18). 
A potential drawback concerning hydrogel-based drug delivery could be that the 
formulation has to be placed precisely at the round window niche. Another problem might 
occur when excessive gel in the middle ear cavity causes transient hearing loss by blocking 
the ossicular chain. Quick elimination of the formulation via the Eustachian tube might limit 
application of hydrogels to treat chronic diseases (83). 
 
Nanoparticles 
Nanoparticles are drug delivery systems with diameters of less than 1000 nm, typically a 
diameter of 200 nm or smaller is requested for otological use (83). They should be 
incorporated into formulations or devices that sustain drug release and prevent the elimination 
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via the Eustachian tube, e.g., by using hydrogels or microcatheters. Different drug delivery 
systems have been investigated to treat inner ear illnesses, e.g., silica nanoparticles, PLGA- or 
GMO-based systems, liposomes, lipid nanocapsules, hyperbranched polylysine nanoparticles, 
polymerosomes, as well as dendrimer-based nanoparticles and SPIONs (18,26). Nanoparticles 
can be used to counteract low drug solubility, problems with degradation, with passage of the 
round window membrane or short half-life of the drug (18). Functionalization of the 
nanoparticles’ surface offer interesting possibilities to target single cell types inside the inner 
ear. An interesting approach to enhance diffusion through the round window membrane might 
be to combine PLGA-nanocarriers with magnetite to release dexamethasone-acetate. After the 
administration of the nanoparticles on the round window niche, a permanent magnet was 
placed on the opposite site of the round window. Drug transport through the membrane has 
been increased using magnetic nanocarriers with a magnet compared to pure diffusion (100). 
For further interesting studies on drug release from nanoparticles the author refers to the 
review published by El Kechai et al. were a vast amount of different strategies are discussed 
in detail (18). 
 
1.3.2.2. Intracochlear drug delivery 
In contrast to intratympanically administered drugs which have to be absorbed via the 
round window membrane, intracochlear delivery offers the potential to release drugs directly 
to the inner ear. Strategies include direct intracochlear injection, drug release using osmotic 
pumps or microcatheters (described in section 1.3.2.1. Intratympanic drug delivery), as well 
as reciprocating perfusion systems and cochlear prosthesis-mediated drug delivery. A rather 
invasive cochleostomy through the round window or the temporal bone is needed to provide 
access to the inner ear (26). 
 
Intracochlear injection 
The intracochlear injection of drugs is mainly used for research, e.g., to conduct 
pharmacokinetic studies or to study the effect of new drugs on inner ear cells. Therefore, a 
few microliters of the drug solution are injected via cochleostomy. Potential drawbacks are 
the short period of drug delivery as well as a possible leakage of cochlear fluids that might 
wash the drug solution out of the cochlea. Furthermore, high drug concentrations at the 
application side might damage the highly sensible inner ear cells. In human, intracochlear 
injection is used only during surgery (18).  
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Osmotic pumps 
Osmotic pumps are used similarly to the microcatheters already described above. Both 
systems can be used to provide intratympanic or intracochlear drug release. The osmotic 
pump can be implanted subcutaneously providing flow rates from 0.1 to 10 µl/h from a 
reservoir containing 0.1 to 2 mL during 1 day up to 6 weeks. Osmotic pressure ensures low 
but permanent drug delivery rates. A drawback is that the flowrate cannot be adjusted in vivo 
(85). Those systems can be used to evaluate new therapies in animal models: betamethasone 
has been administered using an osmotic pump during 14 days following to a damage of the 
right semicircular canal of guinea pigs. Animals treated with the drug showed better recovery 
from the induced vestibular illness compared to non-treated animals (101). 
 
Reciprocating perfusion systems 
Those systems combine microsystems and microfluidics technologies to create new drug 
delivery devices that are able to provide drugs to the inner ear more precisely (83). A 
micropump is infusing and withdrawing inner ear fluids in a cyclic manner nearly 
simultaneously so that the volume inside the cochlea stays constant (26). This device has been 
studied in guinea pigs administering 6,7-dinitroquinoxaline-2,3-dione (DNQX), a glutamate 
receptor blocker. DNQX allowed for following of drug release by recording the Compound 
Action Potential (CAP) (102). A new version of the reciprocating perfusion system has been 
presented recently (26). 
 
Cochlear prosthesis-mediated drug delivery 
Cochlear implants have been used widely since 35 years to cure hearing loss and consist 
of an electrode array that is inserted via cochleostomy inside the scala tympani of the cochlea. 
Different insertion depths are used in practice and in research, ranging from 16 to 31.5 mm 
(26). The usually drug free electrode is coiled up inside the turns of the cochlea providing a 
relatively large surface for potential drug delivery. Different strategies are discussed: 
combining a cochlear implant with a micropump or drug-eluting coatings of the electrode as 
well as introducing the drug directly into the silicone of the electrode (26). The aim is to 
reduce damage of the inner ear cells due to the insertion force during surgery. Therefore, 
dexamethasone-eluting electrodes have been developed and evaluated in vitro and in vivo 
showing promising results (103–105). Another approach is to deliver the drug (or a dye in this 
case) via tiny delivery ports that are connected via the implant with a micropump. The 
distribution of the dye along an artificial cochlea was satisfactory when two outlets served to 
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release the dye (106). Furthermore, electrodes have been coated with hydroxyl ethyl cellulose 
to adjust drug release and have been used to deliver neurotrophic factors, e.g., brain-derived 
neurotrophic factor (BDNF) or neurotrophin-3 (26). 
 
Since silicones are already widely used inside the inner ear, e.g. in the form of cochlear 
implants, this polymer seems to be advantageous to deliver drugs to the inner ear in a 
sustained manner. Therefore, the following chapter will be focused on drug release from 
silicone matrices. 
 
1.4. Drug release from silicone matrices 
The incorporation of drugs within silicone matrices can be very helpful to improve the 
therapeutic efficacy and safety of a large variety of medical treatments. The basic idea is that 
the polymeric system accurately controls the resulting drug release rate during pre-
programmed periods of time. Examples for promising applications include the local delivery 
of drugs to sites of action, which are difficult to reach (without causing major side effects in 
the rest of the human body due to high systemic drug concentrations). This includes for 
instance the treatment of diseases and disorders of the inner ear (107,108). But also local 
treatments of the vagina (109), heart (110), eye (111,112) or scars (113) can be very 
challenging and silicone matrices can be highly beneficial in these cases. Furthermore, 
silicone matrices offer a great potential for the design of advanced intraperitoneal controlled 
release implants (114) and central venous catheters (115). 
Importantly, the release periods can be very long (e.g. several months or years) and the 
resulting advantages for the patient long-lasting. For example, Mond and Stokes (110) 
reported on the benefits of silicone-based, dexamethasone-eluting electrodes in pacemakers, 
which effectively lower the stimulation threshold at the “electrode-tissue interface”. In a 
double-blind human study over 10 years the mean stimulation thresholds for the drug-eluting 
devices remained almost constant (exhibiting a narrow standard deviation), whereas the drug-
free systems showed an unpredictable increase in the threshold values and wide standard 
deviations. Interestingly, 20 % of the dexamethasone is estimated to still remain within the 
silicone matrices even after 10 years implantation in humans (based on the analysis of 
explanted devices). The authors state that drug release may well continue at sufficient levels 
for an additional 10 years. This is a very promising clinical evidence for the benefits of 
silicone-based controlled drug delivery systems. However, the development of such devices is 
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generally very cumbersome, since often long release periods are targeted and so far very little 
information is available on the impact of the device design on the resulting system 
performance (in particular drug release kinetics) in a quantitative way. So, highly time-
consuming and cost-intensive series of trial-and-error experiments are mandatory. 
In order to adjust a desired drug release profile from a silicone matrix, different 
formulation parameters can be varied. For instance, the type of silicone (e.g. with a particular 
type of side chains and contents of amorphous silica) can be altered, different types and 
amounts of additives can be incorporated and/or the initial drug content can be varied. Also, 
the geometry and dimensions of the system might be changed. Both determine the pathway 
lengths, which have to be overcome by the drug to be released. Interesting reports are 
available in literature on the effects of the composition of silicone matrices on the resulting 
drug release kinetics (116–119). For example, Di Colo and co-workers studied the impact of 
adding glycerol, ethylene glycol and poly(ethylene glycol) to silicone disks loaded with 
prednisolone (120,121). Importantly, the presence of these hydrophilic additives effectively 
increased the resulting drug release rate. It has to be pointed out that silicones are generally 
hydrophobic and water penetration into the systems is very limited. Furthermore, commonly 
used silicones do not degrade in the human body. Craig and co-workers (109) published a 
very interesting study on the importance of the solubility of the drug in silicone matrices for 
the resulting release kinetics. Clindamycin, 17-estradiol, 17-estradiol-3-acetate, 17-
estradiol diacetate, metronidazole, norethisterone, norethisterone acetate and oxybutynin 
release was studied from intravaginal rings, prepared by injection molding. Also, Liu et al. 
(105) investigated the impact of the initial drug loading and of the dimensions of differently 
shaped silicone matrices on dexamethasone release. Waever et al. (122) used dexamethasone 
loaded silicone rods and discs for controlled local delivery in order to modulate inflammation 
in islet transplantation, and varied the initial drug loading. 
It has to be highlighted that the underlying mass transport mechanisms in polymeric drug 
delivery systems can be rather complex (123–125). The basic idea is that the presence of the 
polymer prevents immediate drug release upon contact with aqueous body fluids. Generally, 
first water penetrates into the system and dissolves the drug (126). Once dissolved (in the 
form of individual molecules), the drug can diffuse through the polymeric system into the 
surrounding environment. Drug diffusion might take place through an intact polymeric 
network and/or through water filled pores. The amount of water available for drug dissolution 
in the system and the drug solubility in the matrix can be decisive (127). In the case of 
substantial polymer swelling and/or dissolution, important time- and position-dependent 
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changes in the system’s composition might occur over time, altering the conditions for drug 
transport (128). Furthermore, the homogeneity of the initial drug distribution within the 
silicone matrix can be of importance (129). More or less complex mathematical theories can 
be used to quantify the involved mass transport processes and describe drug release from 
polymeric delivery systems (130–133). Also neural networks can be applied (134,135). 
Ideally, the mathematical theory should be mechanistically realistic and take all decisive 
phenomena into account, thus, allowing for the quantitative prediction of the effects of the 
device design on the resulting drug release kinetics (136). Negligible mass transport 
phenomena should not be considered, to keep the model as simple as possible. However, yet 
there is a lack of reliable mathematical theories allowing for such in-silico simulations of the 
impact of formulation parameters on the resulting system performance. 
 
1.5. Objectives 
The objective of this thesis was to develop implants capable of releasing the drug in a 
time controlled manner to the inner ear to treat inner ear diseases. The following steps have 
been selected to achieve this aim: 
 
 Characterization of dexamethasone loaded silicone matrices in vitro to identify easy 
tools allowing for the adjustment of drug release kinetics from thin films and extrudates. 
Therefore, different formulation parameters have been varied: the ratio of PEG addition to the 
silicone, the molecular weight of PEG, the chemical structure of the silicone and the 
dexamethasone loading. Mathematical modeling helped to elucidate the underlying drug 
release mechanisms. 
 
 Development of dexamethasone loaded implants using the most promising silicone. 
Thin films and Ear Cube implants have been prepared and studied in vitro. Additionally, the 
physicochemical properties of Ear Cube implants have been analyzed. 
 
 In vivo study with in situ forming dexamethasone loaded implants to examine the 
feasibility of an implantation of the implant besides the oval window. Additionally, the drug 
released from the implant has been detected directly inside the explanted gerbil cochlea using 
Confocal Laser Scanning Microscopy. 
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2. Materials and Methods 
2.1. Dexamethasone mobility in thin films 
2.1.1. Materials 
Kits for the preparation of silicone elastomers: MED-4011, MED-4035, MED-4055, 
MED-4065, MED-4080, MED-4735, MED-6015, MED-6033, MED-6755, MED50-5438, 
MED-5440 (NuSil Technology, Carpinteria, CA, USA); LSR OOO-50, LSR 25, LSR 40 
(Applied Silicone, Santa Paula, CA, USA); dexamethasone (Discovery Fine Chemicals, 
Dorset, UK); poly(ethylene glycol) (PEG): PEG 400 (Lutrol E400; BASF, Ludwigshafen, 
Germany) and PEG 1000 (Polyglycol 1000; Hoechst, Frankfurt, Germany); calcium chloride 
dihydrate, magnesium sulfate tetrahydrate, potassium chloride, sodium chloride and 4-(2-
hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) (HEPES Pufferan, Carl Roth, 
Lauterbourg, France); acetonitrile and tetrahydrofuran (HPLC grade; Fisher Scientific, 
Illkirch, France). 
 
2.1.2. Preparation of drug loaded films 
Thin dexamethasone-loaded films were prepared using different commercially available 
silicone preparation kits, obtained from 2 suppliers (NuSil Technology and Applied Silicone). 
All kits consisted of 2 parts, which were mixed to initiate crosslinking and, thus, system 
hardening. It has to be pointed out that some of these raw materials were pasty (MED-4735, 
MED-4035, MED-4055, MED-4065, MED-4080), while others were liquid (MED-4011, 
MED-6015, MED-6033, MED-6755, MED50-5438, MED-5440, LSR OOO-50, LSR 25, 
LSR 40). 
Pasty silicone kits: Equal amounts of Parts A and B (approximately 5 g) of the 
preparation kits were passed separately 10 times through a two roll mill (Chef Premier KMC 
560/AT970A; Kenwood, Havant, UK). To initiate polymer crosslinking, both parts were 
manually blended and the mixture was passed 10 times through the mill. Subsequently, 
appropriate amounts of dexamethasone powder (as received) were added and the mixture was 
passed another 40 times through the mill to obtain a homogenous film. Crosslinking was 
completed by a thermal treatment in an oven at 60 °C for 24 h. 
Liquid silicone kits: Equal amounts of Parts A and B (approximately 5 g) (except for 
LSR 25, LSR 40, MED-4011, MED-6015, where 10 Parts A were combined with 1 Part B: 
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approximately 10 g plus 1 g) of the preparation kits were manually blended for 5 min in an 
ice-cooled mortar (the cooling slowed down polymer crosslinking). Subsequently, 
dexamethasone powder (as received) was added and the mixture was manually blended for 
10 min in the ice-cooled mortar. The obtained mass was placed between two Teflon films and 
passed 10 times through a two roll mill (Chef Premier KMC 560/AT970A). Crosslinking was 
completed by a thermal treatment in an oven at 60 °C for 24 h. 
Optionally, 5 or 10 % (w:w) PEG 400 or PEG 1000 was added to the formulation (as 
indicated). In these cases, the PEG was manually blended with the drug in a mortar. The 
obtained drug-PEG mixture was incorporated into the formulations in the same way as the 
drug only (as described above). 
The thickness of the resulting films was determined with a micrometer gauge (Digimatic 
Micrometer; Mitutoyo, Tokyo, Japan). 
 
2.1.3. Preparation of drug loaded extrudates 
Different types of dexamethasone-loaded extrudates were prepared with pasty silicone 
preparation kits. Equal amounts of Parts A and Part B (approximately 5 g) of the preparation 
kits were passed separately 10 times through a two roll mill (Chef Premier KMC 
560/AT970A). To initiate polymer crosslinking, both parts were manually blended and the 
mixture was passed 10 times through the mill. Subsequently, appropriate amounts of 
dexamethasone powder (as received) were added and the mixture was passed another 40 times 
through the mill to obtain a homogenous (and easily deformable) film. The latter was 
transferred into 5 mL polypropylene luer lock syringes (Terumo Europe, Leuven, Belgium) 
and extruded using a texture analyzer (TAXT plus, Stable Micro Systems, Surrey, UK), 
equipped with a self-made syringe fixation device. The obtained extrudates were cured on a 
Teflon sheet (Bytac; Sigma-Aldrich, St. Louis, US) in an oven at 60 °C for 24 h to complete 
crosslinking, followed by manual cutting to the desired length. 
 
2.1.4. Drug release measurements 
Dexamethasone release was measured from thin films and cylindrical extrudates, as 
described in the following section. Each experiment was performed in triplicate. 
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Film pieces were placed into amber glass flasks containing 10 mL (if not otherwise 
stated) artificial perilymph: an aqueous solution of 1.2 mmol calcium chloride dihydrate, 
2 mmol magnesium sulfate tetrahydrate, 2.7 mmol potassium chloride, 145 mmol sodium 
chloride and 5 mmol HEPES Pufferan. The flasks were horizontally shaken in an incubator 
(80 rpm; GFL 3033; Gesellschaft fuer Labortechnik, Burgwedel, Germany) at 37°C. At 
predetermined time points, 1 mL samples were withdrawn and replaced with fresh artificial 
perilymph. The drug concentration in the withdrawn samples was determined by HPLC 
analysis (Thermo Fisher Scientic Ultimate 3000 Series, equipped with a pump: LPG 3400 
SD/RS, an autosampler: WPS-3000 SL, a column compartment: TCC 3000 D/RS and a UV-
Vis detector: VWD-3400RS; Thermo Fisher Scientic, Waltham, USA) (lower quantification 
limit: 6 x 10-7 mg/L; linear range: 0.0001 - 50 mg/L). Samples (100 ȝL) were injected into a 
C18 RP column (Gemini 5 µ C18 110 A, 150 mm x 4.6 mm; Phenomenex, Le Pecq, France) 
(mobile phase = acetonitrile:water 33:67 V:V, flow rate = 1.5 mL/min). Dexamethasone was 
detected at  = 254 nm. 
Cylindrical extrudates were placed into silicone tubes (Helix Medical, Carpinteria, CA, 
USA) containing 1 mL artificial perilymph, which were horizontally shaken at 80 rpm at 
37 °C (GFL 3033). At predetermined time points, the release medium was completely 
renewed and the drug contents in the withdrawn bulk fluid determined by HPLC analysis, as 
described above. 
 
2.1.5. Scanning electron microscopy 
The morphology of thin silicone films was observed using a scanning electron 
microscope (S-4000; Hitachi High-Technologies Europe, Krefeld, Germany). Samples were 
fixed on the sample holder with a ribbon carbon double-sided adhesive and covered with a 
fine carbon layer. Cross-sections were obtained by freezing the films in liquid nitrogen and 
manual breaking. 
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2.2.  Ear Cube implants for Controlled Drug Delivery to the Inner Ear 
2.2.1. Materials 
Kits for the preparation of silicone elastomers: LSR 5 (Applied Silicone, Santa Paula, 
USA); Kwik-Sil (World Precision Instruments, Sarasota, USA); dexamethasone (Discovery 
Fine Chemicals, Dorset, UK); calcium chloride dihydrate, magnesium sulfate tetrahydrate, 
potassium chloride, sodium chloride and 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid 
(HEPES, HEPES Pufferan, Carl Roth, Lauterbourg, France); acetonitrile and tetrahydrofuran 
(HPLC grade; Fisher Scientific, Illkirch, France). 
 
2.2.2. Preparation of drug-loaded silicone matrices 
Ten grams of the “Part A” of the silicone preparation kits were manually blended for 
5 min with appropriate amounts of dexamethasone powder (as received) in an ice-cooled 
mortar. Subsequently, 1 g of the “Part B” of the silicone kits was added and the mixture was 
further manually blended for 10 min in the ice-cooled mortar (to slow down crosslinking). 
The obtained mass was transferred into a 5 mL polypropylene luer lock syringe (Terumo 
Europe, Leuven, Belgium) and degassed under vacuum during 60 min to remove air bubbles. 
 
Figure 2.1. Schematic presentation of the geometries and dimensions (indicated in mm) of a 
“smaller” and a “larger” Ear Cube. The drawing on the right hand side illustrates how Ear 
Cubes can be placed into the oval window.  
 
Thin films (Figure 2.2., left hand side) were prepared using a self-made mold, which 
consisted of a microscope slide covered with 2 layers of a Teflon sheet (Bytac, Sigma 
Ear Cube 
Oval window 
Cuboid 
Cylindrical part 
   MATERIALS AND METHODS 
31 
 
Ear Cube Film 
1x1x0.02 cm 
Aldrich, St. Louis, USA). A hole (6 x 1.5 cm) was cut into the upper Teflon sheet. The 
“silicone kit – drug” mixture was placed into this hole, and a casting knife (Multicator, 
Erichsen, Hemer, Germany) was used to provide a homogeneous film thickness. Crosslinking 
was completed by a thermal treatment in an oven at 60 °C for 20 h. The thickness of the films 
was measured with a micrometer gauge (Digimatic Micrometer, Mitutoyo, Tokyo, Japan). 
Drug-free films were prepared accordingly, omitting the drug. In these cases, larger glass 
slides were used instead of microscope slides and the dimensions of the hole were 10 x 13 cm. 
Ear Cubes (Figure 2.2., right hand side) were prepared by injecting the “silicone kit – 
drug” mixture into customized molds (Neurelec, Vallauris, France) using a texture analyzer 
(TAXT plus, Stable Micro Systems, Surrey, UK). Two types of molds were used to prepare 
“smaller” and “larger” Ear Cube implants. The geometries and dimensions of the latter are 
illustrated in Figure 2.1., upon curing for 20 h at 60 °C the implants formed. They were 
removed from the molds under a microscope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Schematic presentations and macroscopic pictures of the investigated silicone 
matrices loaded with dexamethasone: Thin films and Ear Cubes. The drug loading was 10 % 
in all cases. 
 
2.2.3. Drug release measurements 
Film pieces (1x1x0.02 cm) were placed into amber glass flasks containing 10 mL 
artificial perilymph. The flasks were horizontally shaken (80 rpm) in an incubator (GFL 3033, 
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Gesellschaft fuer Labortechnik, Burgwedel, Germany) at 37 °C. At predetermined time 
points, 1 mL samples were withdrawn and replaced with fresh artificial perilymph. Each 
experiment was performed in triplicate. 
A hole (diameter 0.04 cm) was drilled into the bottom of an Eppendorf vial (0.2 mL), 
which had been cut at half height (Figure 2.3.). One Ear Cube was placed into such a hole. 
The upper part of the Ear Cube was fixed with Kwik-Sil silicone in this Eppendorf vial, which 
was placed into a second Eppendorf vial (0.2 mL) containing 0.1 mL artificial perilymph. The 
orifice at the bottom of the first Eppendorf vial was always immersed in the release medium. 
The system was protected from light and placed in a horizontal shaker at 37 °C (80 rpm, GFL 
3033). At predetermined time points, the release medium in the second Eppendorf vial was 
completely renewed. Each experiment was performed six times. 
The drug concentrations in the withdrawn samples was determined by HPLC analysis 
(Thermo Fisher Scientic Ultimate 3000 Series, equipped with a pump: LPG 3400 SD/RS, an 
autosampler: WPS-3000 SL, a column compartment: TCC 3000 D/RS and a UV-Vis detector: 
VWD-3400RS, Thermo Fisher Scientic, Waltham, USA). Samples (100 ȝL for films, 20 µL 
for implants) were injected into a C18 RP column (Gemini 5 µm C18 110 A, 
150 mm x 4.6 mm, Phenomenex, Le Pecq, France) (mobile phase = acetonitrile:water 
33:67 v:v, flow rate = 1.5 mL/min). Dexamethasone was detected at  = 254 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Schematic presentation (not up to scale) of the experimental set-up used for drug 
release measurements from Ear Cubes. Details are given in the text. 
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2.2.4. Side-by-side diffusion cells 
Drug-free silicone films (9x9x0.02 cm) were placed into horizontal side-by-side diffusion 
cells (2 x 100 mL; Permegear, Hellertown, PA, USA). The donor compartment was filled 
with artificial perilymph saturated with dexamethasone (an excess of drug was present at the 
bottom of the chamber, but was not in contact with the silicone film). The acceptor 
compartment was filled with artificial perilymph. The system was protected from light and 
placed in a horizontal shaker at 37 °C (80 rpm, GFL 3033). At predetermined time points, 
1 mL samples were withdrawn from the acceptor compartment and replaced with fresh 
medium. The dexamethasone concentrations in the samples were determined by HPLC 
analysis, as described above. Each experiment was performed in triplicate. 
 
2.2.5. Swelling kinetics of Ear Cubes 
The upper parts of Ear Cube implants were fixed using stainless steel wire and a drop of 
Kwik-Sil silicone at the caps of Eppendorf vials (2 mL), as illustrated in Figure 2.4. The 
implants were immersed into 2 mL artificial perilymph, and the systems were placed in a 
horizontal shaker at 37 °C (80 rpm, GFL 3033). To monitor potential Ear Cube swelling, an 
optical image analysis system (Nikon SMZ-U, Nikon, Tokyo, Japan), equipped with a Zeiss 
camera (AxioCam ICc 1, Zeiss, Jena, Germany) was used. At predetermined time points, 
photos were taken and the medium was completely renewed. Each experiment was performed 
in triplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Schematic presentation (not up to scale) of the experimental set-up used to 
monitor the potential swelling of Ear Cubes. Details are given in the text.  
Artificial perilymph 
Ear Cube 
Kwik-Sil silicone 
for fixation 
Wire 
80 rpm 
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2.2.6. Scanning electron microscopy 
The morphology of cross-sections of Ear Cubes was studied using a scanning electron 
microscope (S-4000; Hitachi High-Technologies Europe, Krefeld, Germany). Samples were 
fixed with a ribbon carbon double-sided adhesive on the sample holder and covered with a 
fine carbon layer. The cross-sections were obtained by freezing the implants in liquid nitrogen 
and manual breaking. 
 
2.2.7. Thermal analysis (DSC) 
Ear Cubes were placed into open aluminum pans. To avoid ghost peaks, they were cut 
into two parts: the cylinders and cuboids, which were placed next to each other in the pans. 
For reasons of comparison, also the pure drug powder (as received) was studied 
(approximately 2.5 mg). The pans were first cooled to -150 °C and then heated to 280 °C at 
10 K min-1 (DSC Q10, TA Instruments, Guyancourt, France). The DSC was calibrated using 
indium.  
 
2.2.8. X-ray diffraction 
A Panalytical X’pert Pro diffractometer (PANalytical, Almelo, Netherlands) in 
transmission mode with incident beam parabolic mirror (Ȝ Cu, Kα = 1.54 Å) was used to 
record X-ray diffraction patterns. Drug-loaded and drug-free Ear Cubes were cut into two 
parts (cylinders and cuboids), and only the cuboids were placed inside a Lindemann glass 
capillary (diameter 1 mm; Hilgenberg, Malsfeld, Germany), which was subsequently fixed on 
a spinning sample holder. For reasons of comparison, also the pure drug powder (as received) 
was analyzed. 
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2.3.  Trans-Oval-Window Implants: Extended Dexamethasone Release 
2.3.1. Materials 
Kwik-Cast silicone (WPI, Sarasota, FL, USA); dexamethasone (Discovery Fine 
Chemicals, Dorset, UK); polyethylene glycol (PEG) 400 (Lutrol E400; BASF, Ludwigshafen, 
Germany); calcium chloride dihydrate, magnesium sulfate tetrahydrate, potassium chloride, 
sodium chloride, and 4-(2- hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES Pufferan, 
Carl Roth, Lauterbourg, France); acetonitrile and tetrahydrofuran (HPLC grade; Fisher 
Scientific, Illkirch, France); phosphate-buffered saline x 10 solution (PBS; Fisher Scientific); 
image-iT fx signal enhancer (Life Technologies, Saint Aubin, France); ethylenediamine 
tetraacetic acid, paraformaldehyde, Teflon films (Bytac), Triton X-100, fetal bovine serum 
(FBS), ethanol, phalloidin tetramethylrhodamine isothiocyanate, methyl salicylate, benzoate 
benzyl, 4‘,6-diamidino-2-phenylindole (DAPI) and fluoroshield (Sigma-Aldrich, St Quentin 
Fallavier, France); Image-iT fx solution (Molecular Probes, Eugene, OR, USA); rabbit 
polyclonal dexamethasone antibody (ABCAM, Cambridge, UK); goat anti-rabbit IgG-Alexa 
488 (Jackson Immunoresearch Laboratories, West Grove, PA, USA); buprenorphine 
(Sogeval, York, UK); lidocaine hydrochloride (AstraZeneca, Reims, France); pentobarbital 
362.9 mg/mL, injectable solution (TVM, Lempdes, France). 
 
2.3.2. Preparation of drug-loaded Matrices 
2.3.2.1. Thin Films 
Thin dexamethasone loaded films based on Kwik-Cast silicone were prepared as follows: 
PEG 400 and dexamethasone powder (both as received) were blended manually (mass 
ratio = 1:2) in a mortar. This drug-PEG blend was incorporated separately into Parts A and B 
of the Kwik-Cast silicone preparation kit in a mortar. The drug-PEG-Part A and drug-PEG-
Part B blends were then placed separately into the two chambers of the dual syringe injection 
system provided by the supplier of Kwik-Cast (WPI). The contents of the two chambers were 
blended during ejection through the mixer tip (600009, WPI) onto a Teflon sheet. Thin films 
were subsequently prepared with a casting knife (Multicator 411; Erichsen, Hemer, 
Germany). Crosslinking completed spontaneously at room temperature within less than 
30 min. The thickness of the films was determined with a micrometer gauge (Digimatic 
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Micrometer; Mitutoyo, Tokyo, Japan). The final percentages of PEG 400 and dexamethasone 
in the films were 5 and 10 %, respectively. 
 
2.3.2.2. In-situ forming implants 
Implants were prepared using the dual syringe injection system for Kwik-Cast provided 
by the supplier (WPI). Each chamber contained either Part A or B of the silicone preparation 
kit, blended with dexamethasone and PEG (the blends were prepared as described in the 
section Preparation of Drug-loaded Films). The contents of the two chambers were mixed 
during ejection through the mixer tip (600009, WPI). One drop of this liquid was placed at the 
bottom of an Eppendorf vial (0.2 mL) into which a hole with a diameter of 0.35mm had been 
drilled (Figure 2.5., left hand side). The liquid filled the bottom part of the vial including the 
hole and hardened within a few minutes at room temperature. 
 
 
Figure 2.5. Schematic presentation of an implant formed at the bottom of an Eppendorf vial 
and the set-up used for in vitro drug release measurements (left and right hand side 
respectively). 
 
2.3.3. Drug Release Measurements 
2.3.3.1. Thin Films 
Film pieces (1x1x0.01 cm) were placed into amber glass flasks containing 10 mL 
artificial perilymph. The flasks were horizontally shaken (80 rpm) in an incubator (GFL 3033, 
Gesellschaft fuer Labortechnik, Burgwedel, Germany) at 37 °C. At predetermined time 
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points, 1 mL samples were withdrawn and replaced with fresh artificial perilymph. Each 
experiment was performed in triplicate. 
 
2.3.3.2. In-situ forming implants 
An Eppendorf vial (0.2 mL) into which a hole (diameter 0.35 mm) had been drilled at the 
bottom and in which an implant had been formed as described above, was cut at half height 
(Figure 2.5., right hand side). The bottom part of this first Eppendorf vial was placed into a 
second Eppendorf vial (0.2 mL), which was (partly) filled with 100 µL artificial perilymph 
(37 °C). The inner Eppendorf vial was manually fixed within the second Eppendorf vial and 
its orifice was always immersed in the artificial perilymph. The entire system was protected 
from light and agitated at 80 rpm in a horizontal shaker at 37 °C (GFL 3033). At 
predetermined time points, the release medium was completely renewed. Each experiment 
was performed nine times. 
The drug concentrations in the withdrawn samples were determined by high-performance 
liquid chromatography analysis (Varian Prostar 230, equipped with an autosampler: Prostar 
410 and UV-Vis detector: Prostar 325; Varian, Les Ulis, France). Samples (100 µL for films, 
20 µL for implants) were injected into a C18 RP column (Gemini 5u C18 110A, 150mm x 4.6 
mm; Phenomenex, Le Pecq, France) (mobile phase = acetonitrile:water 33:67 V:V, flow 
rate = 1.5 mL/min). Dexamethasone was detected at  = 254 nm. 
 
The author wants to thank Julie Sircoglou who conducted the in vivo experiments 
presented in this study. 
 
2.3.4. Gerbil Study 
The animal study received prior approval from the French Ministry of Agriculture and 
the Ethic Committee for Animal Experimentation (protocol no. 01225.01). Seventeen 
Mongolian gerbils (Meriones unguiculatus; Charles Rivers, Saint Germain sur l’Arbresle, 
France), 10 months old (approximately 60 g weight) and of either sex, were divided into three 
groups (Figure 2.6.): 
 
(1) A verum group (n = 13) that received the trans-oval window implants. After 20 min, 7 
and 30 days animals were sacrificed and tissues analyzed. 
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(2) A control group, which received an intratympanic injection of an 8 % dexamethasone 
solution on day 0, 1, and 2 (0.1 mL, bilaterally) (n = 2). The animals were sacrificed on day 3 
and the tissues analyzed with primary and secondary antibody (positive control group), or 
secondary antibody only (negative control group). 
 
(3) Gerbils, which received no treatment, were sacrificed after 20 min for tissue analysis 
(negative control group) (n = 2). 
 
 
 
Figure 2.6. Design of the in vivo gerbil study. Details are given in the text. 
 
2.3.5. Implantation Procedure 
After anesthetic induction (mixture of 5 % isoflurane and 0.7 L/min oxygen), animals 
were anaesthetized via an inhalation mask (mixture of 2 % isoflurane and 0.7 L/min oxygen). 
In addition, 0.20 mL of a 1 % lidocaine solution was subcutaneously injected at the surgical 
site for local anesthesia. 
The stapes area was exposed by a submandibular approach under microscope in sterile 
conditions. The auditory bulla was opened between two semicircular canals to expose the oval 
window (Figure 2.7.). A hole (0.35 mm in diameter) was drilled at the medial edge of the oval 
window using a microdrill handpiece (drill Osseostap, Bien Air, Bien Air France Sarl 
Surgery, Pantin, France). A drop of a liquid mixture of Parts A and B of the Kwik-Cast 
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preparation kit, containing 10 % dexamethasone and 5 % PEG 400 (prepared as described in 
the section Preparation of drug-loaded Matrices) was placed onto the perforation site, next to 
the stapes’ footplate. The implant hardened within a few minutes (Figure 2.7.). Buprenorphine 
(0.03 mg/kg) was injected intraperitoneally for analgesia after surgery.  
 
 
 
Figure 2.7. Exposition of the middle and inner ear after opening the auditory bulla of gerbil 
(left hand side: right ear) and Insertion of the implant after micro-shaping on the lateral edge 
of the oval window (right hand side: left ear): A) surgical implantation site, B) oval window, 
C) stapes, D) cochlea, E) lateral semicircular canal, F) stapedial artery, G) round window, and 
H) trans-oval-window implant. To compare these images with a 3D-model of the cochlea 
please refer to Figure 1.4. 
 
2.3.6. Cochleae Preparation for Further Analysis 
At predetermined time points, gerbils were anesthetized (with a mixture of 5 % isoflurane 
and 0.7 L/min oxygen) and sacrificed by a lethal intraperitoneal injection of sodium 
pentobarbital (180 mg/kg). The following types of tissue samples were prepared: 
 
(i) The whole cochlea: The auditory bulla was opened to dissect the cochlea and 
remove it from the otic capsule. A small hole was drilled into both, the apex of the 
cochlea and the round window with a fine needle. Samples were fixed with 
paraformaldehyde (4 %) at 4 °C for 24 h. Decalcification was achieved by 
immersion into a 10 % ethylenediamine tetraacetic acid solution in PBS for 7 days. 
Specimens were rinsed with 70 % ethanol and stored at 4 °C. 
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(ii) Cochlea sections: Upon cochlea dissection, fixation and decalcification [as 
described in (i), except for ethanol rinsing], cochleae were placed in an aqueous 
sucrose solution (30 %) for 24 h and then in the embedding medium ‘‘OCT’’ 
(Optimal Cutting Temperature, Cellpath, Newtown, UK). The samples were deep-
frozen in liquid nitrogen and stored at -20 °C. Twenty micrometers of sections 
were prepared with a cryostat (Leica CM3050S; Leica Microsystemes SAS, 
Nanterre, France) and placed on glass slides (Superfrost plus; Fisher Scientific). 
(iii) The organs of Corti: Samples were dissected by removing the bony labyrinth of 
the whole cochleae and fixed with paraformaldehyde (4 %) at 4 °C for 30 min. 
 
2.3.7. Immunohistochemistry 
2.3.7.1. Silicone Films 
Kwik-Cast silicone-based film pieces (0.5x0.5x0.01 cm) loaded with 10 % 
dexamethasone and containing 5 % PEG 400 were incubated in a blocking solution (0.1 % 
Triton X-100, 10 % FBS in PBS) at room temperature under gentle agitation for 30 min. 
Then, an indirect immunolabeling was performed. The film pieces were exposed to a solution 
of a primary rabbit polyclonal dexamethasone antibody in buffer solution (0.1 % Triton X- 
100, 20 % FBS in PBS) (1:100) at 4 °C overnight under gentle agitation. Then, the samples 
were rinsed three times with PBS for 5 min. Afterward, the film pieces were exposed to a 
solution of AlexaFluor488 secondary antibodies in PBS (1:400) at 4 °C for 4 h, followed by 
three times rinsing with PBS for 5 min. Finally, the samples were placed on a strip (Ibidi, 
mSlide, ref. 80826) for confocal microscopy. 
 
2.3.7.2. Tissue Samples 
Whole cochleae were immersed in Image-iT fx solution for 30 min, and subsequently 
washed three times in PBS containing 0.1 %Triton X-100 for 30 min. The samples were then 
exposed to a 30 µg/mL phalloidin tetramethylrhodamine isothiocyanate solution in PBS for 
30 min and then incubated in a blocking solution (0.1 % Triton X-100, 10 % fetal bovine 
serum in PBS) at room temperature under gentle agitation for 2 h. The cochleae were exposed 
to a solution of a primary dexamethasone antibody for 3 days and then to a solution of 
AlexaFluor488 secondary antibodies for 12 h (as described in the section Silicone Films). The 
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samples were then incubated in 0.25 µg/mL DAPI solution in PBS for 30 min. Specimens 
were rinsed three times with PBS, for 15 min each, after each step. 
After three consecutive ethanol baths (ethanol 70, 95, and 100 %) for 2 h each, 
dehydrated cochleae were transferred into a clearing solution of MSBB (mixing of five parts 
methyl salicylate and threeparts benzoate benzyl) diluted in a solution of 1:1 absolute ethanol. 
Samples were placed into successive MSBB baths for 2, 4, and 12 h and protected from light 
at room temperature with gentle agitation. 
Cochlea sections and organs of Corti were treated in the same way as whole cochleae, but 
applying shorter exposure times. These samples were mounted with fluoroshield at the end of 
these steps. 
Samples from nontreated animals were treated in the same way, using primary and 
secondary antibodies (serving as negative controls). Samples from gerbils receiving 
dexamethasone solution intratympanically were treated either with primary and secondary 
antibodies (serving as positive controls), or with secondary antibodies only (serving as 
another negative control).  
 
2.3.7.3. Confocal Laser Scanning Microscopy 
A Confocal Laser Scanning Microscope, equipped with 10x/0.3, 20x/0.6 objectives and 
40x/1.3, 63x/1.4 immercell oil objectives (LSM 710; Carl Zeiss, Jena, Germany) was used. 
Three lasers were applied: a 405-nm UV diode, a 488-nm argon laser, and a 561-nm DPSS 
diode contributed to excite DAPI (nuclear labeling), Alexa 488 (dexamethasone labeling) and 
Phalloidin TRITC (actin cytoskeleton labeling), respectively. Serial sections from the three-
dimensional reconstruction were acquired using 2 and 4 µm Z-steps. Snapshot of several 
regions of the sample were acquired by fast-scanning step. The Z-stack images allowed 
obtaining maximum projections. Images were acquired and analyzed with the ZEN software. 
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3. Results and Discussion 
3.1. Dexamethasone mobility in thin films 
3.1.1. Effects of PEG addition 
The diagrams on the left hand side of Figure 3.1 show the absolute amounts of 
dexamethasone released from thin films with an initial drug loading of 10 % into artificial 
perilymph. Three types of liquid silicone preparation kits were used (MED-4011, MED-6015, 
MED-6755). Optionally, 5 or 10 % PEG 1000, or 10 % PEG 400 was added (as indicated). 
The symbols represent the experimentally measured results. Clearly, the addition of different 
amounts of PEG had a strong effect on the resulting drug release kinetics, whereas the 
variation of the type of PEG (and of the type of silicone) had a moderate impact on 
dexamethasone release in the investigated ranges. As it can be seen: (i) Increasing PEG 
amounts led to increasing drug release rates. (ii) Higher molecular weight PEG led to faster 
drug release compared to lower molecular weight PEG. (iii) The absolute dexamethasone 
release rate generally increased in the following rank order: MED-4011 < MED-6015 < 
MED-6755, irrespective of the presence/absence of PEG. 
In order to quantitatively evaluate these results, an analytical solution of Fick’s second 
law of diffusion was used to describe the experimentally measured dexamethasone release 
kinetics. The model is based on the assumption that drug diffusion within the polymeric films 
is the dominant mass transport step. Furthermore, the theory considers initially homogeneous 
distributions of the drug, silicone and PEG within the films, perfect sink conditions and 
constant drug diffusion coefficients. Importantly, the model does not take into account limited 
drug solubility effects. Under these conditions, the following equation can be derived and 
used to quantify dexamethasone release from the investigated silicone films, optionally 
containing different amounts and types of PEG (137): 
 





 
 0n 2
22
22
t
L
tπ1)D(2n
exp
1)(2n
1
π
81
M
M
  (1)
 
 
where Mt and M∞ denote the absolute cumulative amounts of drug released at time t and 
infinity, respectively; n is a dummy variable, D the “apparent” diffusion coefficient of the 
drug within the polymeric system; L represents the thickness of the film.  
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Figure 3.1. Effects of adding different types and amounts of PEG to thin films prepared with 
liquid silicone preparation kits (MED-4011; MED-6015; MED-6755) on the resulting 
dexamethasone release kinetics: left hand side – absolute drug release; right hand side - 
normalized relative drug release (film dimensions: 1x1x0.02 cm; 10 % drug loading). The 
symbols represent the experimentally measured results, the solid curves the fitted theory 
(Eq. 1).  
0
10
20
30
40
50
60
70
80
90
100
0
20
40
60
80
100
0 0.002 0.004 0.006 0.008 0.01
dr
ug
 re
le
as
ed
, %
time/thickness2, d/µm2
10 % PEG 1000
10 % PEG 400
5 % PEG 1000
no PEG
fitted theory
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0
0.5
1
1.5
0 20 40 60
dr
ug
 re
le
a
se
d,
 m
g
time, d
10 % PEG 1000
10 % PEG 400
5 % PEG 1000
no PEG
fitted theory
0
10
20
30
40
50
60
70
80
90
100
0
20
40
60
80
100
0 0.0005 0.001 0.0015 0.002
dr
ug
 re
le
as
ed
, %
time/thickness2, d/µm2
10 % PEG 1000
10 % PEG 400
5 % PEG 1000
no PEG
fitted theory
0.00
0.20
0.40
0.60
0.80
1.00
1.20
1.40
0
0.5
1
1.5
0 20 40 60
dr
ug
 re
le
as
ed
, m
g
time, d
10 % PEG 1000
10 % PEG 400
5 % PEG 1000
no PEG
fitted theory
0
10
20
30
40
50
60
70
80
90
100
0
20
40
60
80
100
0 0.0005 0.001 0.0015 0.002
dr
ug
 re
le
as
ed
, %
time/thickness2, d/µm2
10 % PEG 1000
10 % PEG 400
5 % PEG 1000
no PEG
fitted theory
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0
0.5
1
1.5
0 20 40 60
dr
ug
 re
le
as
ed
, m
g
time, d
10 % PEG 1000
10 % PEG 400
5 % PEG 1000
no PEG
fitted theory
   RESULTS AND DISCUSSION 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Effects of adding different types and amounts of PEG to thin films prepared with 
liquid silicone preparation kits (MED-4011; MED-6015; MED-6755) on the resulting degree 
of sample saturation (film dimensions: 1x1x0.02 cm; 10 % drug loading). 
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The curves in Figure 3.1 show the fittings of Eq. 1 to the experimentally determined 
dexamethasone release kinetics (the correspondent degree of drug saturation for each curve is 
shown in Figure 3.2). As it can be seen, good agreement between experiment and theory was 
obtained in all cases, irrespective of the presence/absence of PEG. This can serve as an 
indication for the fact that drug diffusion indeed plays a major role in the control of drug 
release from these systems (135). If this is true, the observed drug release kinetics can be 
normalized with respect to the film thickness (which slightly varied from sample to sample). 
It has to be pointed out that the film thickness determines the length of the diffusion pathways 
to be overcome and, hence, affects the drug release rates. Consequently, the observed drug 
release kinetics shown on the left hand side of Figure 3.1 should be viewed with some 
cautionμ Not only the variation of the films’ composition impacts drug release, but also 
unintended variations in the thickness of the film samples. To avoid this bias, the results were 
normalized according to Eq. 1μ Instead of the “time”, the “time/thickness²” is plotted on the x-
axes in the diagrams on the right hand side of Figure 3.1. In addition, the percentage of drug 
release is plotted on the y-axes (instead of the absolute amounts). This normalization of the 
drug release rates allows for a more reliable comparison of the release profiles if the effects of 
the film composition are to be studied. Unfortunately, sometimes in the literature drug release 
kinetics from films of different composition and different thickness are compared without 
normalization, and the impact of the film formulation and the impact of the film thickness are 
not always appropriately distinguished. As it can be seen on the right hand side of Figure 3.1, 
the above described general tendencies remained the same, while the relative importance of 
some effects were altered. 
Importantly, based on the fittings in Figure 3.1 (curves), the “apparent” diffusion 
coefficient of dexamethasone in the investigated silicone films (optionally containing 
different types and amounts of PEG) could be determined. This parameter can be used as a 
measure for the mobility of the drug within the polymeric matrices. Figure 3.3 shows its 
dependence on the type and amount of added PEG for the investigated silicone types, ranging 
from D = 5.51 ± 1.71 to 64.54 ± 0.64 x 10-14 cm2/s for MED-4011, from D = 7.59 ± 0.58 to 
72.04 ± 17.96 x 10-14 cm2/s for MED-6015 and from D = 22.41 ± 0.16 to 232.41 
± 5.78 x 10-14 cm2/s for MED-6755. It has to be pointed out that Eq. 1 does not take limited 
drug solubility effects into account. Since the amounts of water penetrating into the systems 
and the solubility of the drug are limited, it can be expected that not all of the drug is rapidly 
dissolved. SEM pictures revealed that small drug crystals were homogenously distributed 
throughout the films, irrespective of the type of silicone (also, all films were opaque). 
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Figure 3.3. Impact of the addition of different types and amounts of PEG to thin silicone 
films prepared with liquid silicone preparation kits (MED-4011; MED-6015; MED-6755) on 
the resulting “apparent” dexamethasone diffusion coefficient (determined based on the fittings 
shown in Figure 3.1). 
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Figure 3.4 shows two examples. Thus, dissolved and non-dissolved dexamethasone are 
likely to co-exist during prolonged periods of time within the matrices. Importantly, only 
dissolved drug is available for diffusion. Consequently, the determined drug diffusivities are 
“biased” or “lumped” values, which is emphasized in this article using the term “apparent” 
drug diffusion coefficient. The real drug diffusivity is likely to be much higher: In reality, the 
non-dissolved drug is not able to diffuse, but the applied model assumes all drug to be able to 
diffuse. A much more comprehensive mathematical model is required to more realistically 
describe the exact mass transport phenomena in the investigated systems (including time- and 
position-dependent matrix compositions and drug diffusivities). But such a model must be 
based on a much broader experimental data basis (e.g. including information on structural 
changes of the films during drug release). Based on the available data, the best parameter to 
describe the mobility of the drug in the silicone matrices is the “apparent” drug diffusivity 
discussed above: Importantly, it takes all the practically relevant effects directly or indirectly 
into account. In particular, this “lumped” parameter is highly useful for the comparison of 
dexamethasone mobility in the investigated silicone films of different composition. 
 
 
Figure 3.4. Scanning electron microscopy pictures of cross-sections of thin silicone films 
loaded with 10 % dexamethasone, prepared with: a) MED-5440, b) MED-6755 (scale bar = 
5 µm). The arrows indicate drug crystals. 
 
As it can be seen in Figure 3.3, the above described general effects of the addition of 
different amounts and types of PEG on dexamethasone release are confirmed by the analysis 
based on the “apparent” drug diffusivity (being a quantitative measure for drug mobility in the 
silicone matrices): (i) The addition of increasing amounts of PEG to the system leads to 
higher drug mobility. This can probably be attributed to the fact that PEG is much more 
hydrophilic than the investigated silicones, thus, the presence of increasing amounts of PEG 
drives more and more water into the system. Consequently, more drug can dissolve and the 
permeability of the dissolved drug is increased. This is true for all the investigated silicone 
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types. (ii) Interestingly, at the same PEG content, the higher molecular weight PEG 1000 
leads to faster drug release than the lower molecular weight PEG 400, in all cases. The exact 
reasons for this phenomenon are not fully understood. Eventually, the PEG distribution in the 
films is dependent on the PEG molecular weight, resulting for instance in differently 
structured water-filled channels, through which the drug can diffuse. (iii) The dexamethasone 
mobility depends on the type of silicone, generally increasing in the following rank order: 
MED-4011 < MED-6015 < MED-6755. This aspect will be discussed in more detail in the 
following section. 
Note that all the results shown in Figures 3.1, 3.2 and 3.3 were obtained with liquid 
silicone preparation kits. Importantly, also pasty kits are available on the market. The 
difference “pasty-liquid” can be decisive in practice, e.g. strongly affecting the manufacturing 
procedure of the drug delivery system. The effects of the addition of different amounts and 
types of PEG on dexamethasone release from films prepared with the pasty silicone 
preparation kits MED-4065, MED-4080 and MED-4735 are illustrated in Figure 3.5 (note that 
in the case of MED-4735 and 10 % PEG 400 the resulting films were too sticky to be 
handled). The correspondent degree of drug saturation for each curve is shown in Figure 3.6. 
As in the case of liquid silicone preparation kits, the addition of increasing amounts of PEG 
led to increasing drug release rates. However, in contrast to the investigated liquid kits, the 
addition of shorter chain PEG 400 led to faster drug release compared to longer chain 
PEG 1000. This difference in the impact of the molecular weight of the added PEG to liquid 
versus pasty silicone preparation kits might be explained as follows: PEG 400 is liquid, 
whereas PEG 1000 is solid. The mixing with the liquid and pasty kits might lead to blends 
with different degrees of homogeneity, and the PEG affinity to preparation kit compounds 
might depend on the PEG chain length and type of kit. These differences can lead to different 
inner film structures, resulting in an altered apparent drug mobility. In the case of pasty 
silicone preparation kits, films might result, from which shorter chain PEG 400 more easily 
leaches out into the surrounding bulk fluid than longer chain PEG 1000, and/or the shorter 
chain PEG 400 might create a higher osmotic pressure and lower viscosity in water-filled 
pores. Potential differences in the PEG distribution within the silicone matrix might also lead 
to different degrees of polymer-polymer interactions (e.g. MED-4735-based films containing 
10 % PEG 400 were too sticky to be handled, thus, PEG might also act as a plasticizer for the 
silicones). Such effects might contribute to the observed faster drug release from PEG 400-
containing films compared to PEG 1000-containing films prepared with pasty preparation 
kits.  
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Figure 3.5. Effects of adding different types and amounts of PEG to thin films prepared with 
pasty silicone preparation kits (MED-4065; MED-4080; MED-4735) on the resulting 
dexamethasone release kinetics (absolute drug release) (film dimensions: 1x1x0.02 cm; 10 % 
drug loading). The symbols represent the experimentally measured results, the solid curves 
the fitted theory (Eq. 1) in case of good agreement, and the dotted curves show the fitted 
theory (Eq. 1) in case of poor agreement.  
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Figure 3.6. Effects of adding different types and amounts of PEG to thin films prepared with 
pasty silicone preparation kits (MED-4065; MED-4080; MED-4735) on the resulting degree 
of sample saturation (film dimensions: 1x1x0.02 cm; 10 % drug loading).  
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As in the case of liquid silicone preparation kits, Eq. 1 was fitted to the experimentally 
determined dexamethasone release kinetics (curves in Figure 3.5). Interestingly, only in the 
case of PEG-free systems good agreement between theory and experiment was observed 
(solid curves), indicating that diffusion is likely to play a major role for the control of drug 
release. In contrast, substantial and systematic deviations were observed between theory 
(dotted curves) and experiment (symbols) in the case of all PEG-containing films: Drug 
release was underestimated at early time points and overestimated at later time points. This 
clearly indicates that not only diffusional mass transport is decisive in these systems. This is 
why no “apparent” drug diffusivities could be determined for PEG-containing silicone 
matrices prepared with pasty kits, and the respective drug release kinetics could not be 
normalized with respect to the film thickness. Thus, the arbitrary variations in the thickness of 
the film samples referred to in Figure 3.5 partially contribute to the observed differences in 
drug release. However, since the film thickness variations were of the same order of 
magnitude as the variations observed with film samples prepared with liquid silicone 
preparation kits (Figure 3.1), it can be expected that the impact of the investigated film 
formulation parameters is much more important than the impact of the arbitrary variations in 
the film thickness. 
 
3.1.2. Effects of the type of silicone  
The impact of the type of silicone, including the type of side chains and contents of 
amorphous silica, on dexamethasone release from thin films into artificial perilymph is shown 
in Figure 3.7. The films were prepared with the liquid preparation kits MED-6033 and 
MED-6015 (containing dimethyl-side chains) as well as MED-5440 and MED-50-5438 
(containing fluorine-side chains). MED-5440 and MED-50-5438 contained 19 and 20 % 
amorphous silica, respectively. All films were free of PEG. As it can be seen, the type of 
silicone had a significant impact on drug release. Note that the films in Figure 3.7 had a larger 
surface area than those in Figures 3.1 and 3.5. So, a direct comparison of the absolute drug 
release rates between the three figures should be viewed with some caution. The curves in 
Figure 3.7 show the fittings of Eq. 1 to the experimentally measured drug release kinetics. As 
it can be seen, good agreement was obtained in all cases, further confirming that in all PEG-
free silicone systems diffusional mass transport seems to be decisive for the control of drug 
release. Thus, also in these cases, the release rates can be normalized to the film thickness, as 
shown in Figure 3.7b.  
   RESULTS AND DISCUSSION 
52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Effects of varying the type of silicone on the resulting: a) absolute dexamethasone 
release, b) normalized relative drug release, c) “apparent” dexamethasone diffusion 
coefficient from/in thin films, and d) degree of sample saturation (dimensions: 
3.5x3.5x0.1 cm; dexamethasone loading 10 %). In a) and b) the symbols show the 
experimental results and the curves the fitted theory (Eq. 1). The diffusivities illustrated in c) 
were determined based on the fittings shown in a) and b). MED-6033 and MED-6015 contain 
dimethyl-side chains, MED-5440 and MED-50-5438 contain fluorine-side chains. All films 
were free of PEG. 
 
When comparing the dexamethasone release kinetics from the films prepared with the 
MED-6015 (open triangles; virtually overlapping with the open diamonds of MED-6033) and 
MED-5440 (filled squares) kits, the importance of the film thickness normalization becomes 
evident: In Figure 3.7a, MED-5440-based films show faster release than MED-6015-based 
films, but this difference can be attributed to the difference in film thickness (and not to the 
different film composition or structure): The average film thicknesses of MED-5440-based 
films were about 35 % smaller than the average film thicknesses of MED-6015-based films.  
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Figure 3.8. Effects of varying the type of silicone on the resulting: a) absolute dexamethasone 
release, b) normalized relative drug release, and c) degree of sample saturation (dimensions: 
1x1x0.02 cm; dexamethasone loading 10 %). The symbols in a) and b) show the experimental 
results, the curves the fitted theory (Eq. 1). All films were free of PEG. 
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Figure 3.9. Effects of varying the type of silicone on the resulting “apparent” dexamethasone 
diffusion coefficient from/in thin films (dimensions: 1x1x0.02 cm; dexamethasone loading 
10 %). The diffusivities illustrated in Figure 3.9 were determined based on the fittings shown 
in Figure 3.8a and b. All films were free of PEG. 
 
The shorter diffusion pathways in MED-5440-based films led to faster drug release. 
Importantly, this “film thickness effect” is avoided upon appropriate normalization of the 
results: Figure 3.7b shows that the mobility of dexamethasone is higher in MED-6015-based 
films (open triangles) than in MED-5440-based films (filled squares). Thus, erroneous 
conclusions can easily be drawn when comparing non-normalized drug release kinetics. 
Again, based on the fittings of Eq. 1 to the experimental results, the “apparent” 
dexamethasone diffusion coefficients in the investigated silicone films could be determined: 
As it can be seen in Figure 3.7c, the type of silicone can effectively be used to adjust a desired 
dexamethasone mobility in the polymeric matrices. But note that the values remain relatively 
small (D = 2.02 ± 0.31 x 10-14 cm2/s for silicone MED-6033) compared to those of PEG-
containing films (D = 232.41 ± 5.78 x 10-14 cm2/s for silicone MED-6755 with 10 % PEG 
1000 ) (Figure 3.3, the y-axes being differently scaled). 
The absolute dexamethasone release kinetics from films prepared using different types of 
pasty and liquid silicone preparation kits are shown in Figure 3.8a. Note that the film 
dimensions were different from those of the films shown in Figure 3.7. Thus, a direct 
comparison is not straightforward. Fitting Eq. 1 to the experimentally determined drug release 
kinetics, good agreement between theory and experiment was obtained in all cases (curves 
and symbols), further confirming the dominant role of diffusional mass transport for the 
control of drug release from PEG-free silicone films. The respective normalized 
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dexamethasone release kinetics are shown in Figure 3.8b. When comparing the latter to 
Figure 3.7b, note the different scaling of the x-axes. As it can be seen, the dexamethasone 
release rate can be varied to a certain extent by varying the type of silicone. Figure 3.9 shows 
the “apparent” diffusion coefficients of the drug in these systems, determined based on the 
fittings illustrated in Figures 3.8a and b. Roughly, a desired dexamethasone diffusivity can be 
adjusted in the range of 3.5 and 22.4 x 10-14 cm²/s using these silicone preparation kits. 
 
3.1.3. Impact of the initial drug loading 
Another formulation parameter, which can potentially be altered in order to adjust a 
desired drug mobility within silicone matrices (and, hence, desired drug release profiles), is 
the initial drug loading of the system. The symbols in Figure 3.10a show the experimentally 
measured absolute amounts of dexamethasone released from films with an initial drug content 
of 10, 30, 40 and 50 %, respectively. All films were prepared with the MED-4011 silicone kit, 
and were free of PEG. Note that intentionally a higher volume of release medium was used in 
these cases (900 ml instead of 10 mL) in order to avoid potential drug saturation effects in the 
surrounding bulk fluid. Clearly, the absolute drug release rate increased with increasing initial 
drug loading. This can at least partially be explained by the increasing porosity of the 
polymeric matrix upon drug exhaust, resulting in an increased mobility for the remaining 
drug. The respective relative amounts of dexamethasone released from the films as a function 
of time are illustrated in Figure 3.10b. Interestingly, the relative release rates were very 
similar for the drug loadings 10, 30 and 40 % (but some caution should be paid, since these 
curves are not normalized to the films’ thicknesses). Again, fitting Eq. 1 to the experimental 
results led to good agreement in all cases (curves and symbols in Figure 3.10). Thus, 
irrespective of the initial drug content, diffusional mass transport seems to play a dominant 
role in all PEG-free silicone matrices investigated in this study. 
Importantly, this fact allows normalizing the observed drug release kinetics with respect 
to the films’ thicknesses. As it can be seen in Figure 3.10c, the relative normalized drug 
release rates are virtually overlapping for films loaded with 10 and 30 % dexamethasone. 
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Figure 3.10. Impact of the initial drug loading (indicated in the diagrams) on dexamethasone 
release from thin films in 900 mL artificial perilymph: a) absolute drug release, b) relative 
drug release, and c) normalized relative drug release. All films (dimensions 1x1x0.05 cm) 
were based on MED-4011 and free of PEG. The symbols represent the experimentally 
measured results, the solid curves the fitted theory (Eq. 1).  
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Somewhat faster drug release was observed at an initial drug loading of 40 %, and 
substantially faster drug release at 50 % initial dexamethasone content. The reason for this 
phenomenon might at least partially be related to the percolation theory: Above a certain, 
critical threshold value for the drug loading, a continuous 3-dimensional network of drug 
particles is created (as shown previously, dexamethasone is likely to be dispersed in the 
silicone matrix in the form of small particles (135)). Thus, water can more easily penetrate 
into the system upon drug dissolution, and the remaining drug can more rapidly leach out into 
the surrounding bulk fluid (through water filled pores, and not through an intact silicone 
network). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Impact of the initial drug loading (indicated in the diagrams) on the: a) degree of 
sample saturation, and b) “apparent” drug diffusion coefficient of dexamethasone in thin 
silicone films (determined via the fittings shown in Figure 3.10). The films (dimensions 
1x1x0.05 cm) were based on MED-4011 and free of PEG. The release medium was 900 mL 
artificial perilymph.  
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Figure 3.11a shows that perfect sink conditions were provided throughout the duration of 
the experiments (the solubility of dexamethasone in the release medium at 37 °C is 82.3 ± 
1.7 mg/L (104)). Even at an initial drug content of 50 %, the degree of bulk fluid saturation 
(with dexamethasone) did not exceed 3 % (note that this is the degree of drug saturation in the 
release medium outside of the films, not within the films). Importantly, the fittings shown in 
Figure 3.10, again, allowed the determination of the respective “apparent” dexamethasone 
diffusion coefficients in the investigated silicone matrices, now as a function of the initial 
drug content. As it can be seen in Figure 3.11b, the drug mobility in the polymeric systems 
could be substantially increased when increasing the initial drug content (from D = 7.45 ± 
0.53 to 38.89 ± 4.81 x 10-14 cm2/s for silicone loaded with 10 and 50 % drug respectively ). 
However, the obtained D values were still much lower than those observed upon addition of 
different types and amounts of PEG (Figure 3.3). This can at least partially be explained by 
the higher water-solubility of PEG compared to dexamethasone. 
It has to be pointed out that these “apparent” diffusion coefficients do not depend on the 
system geometry and dimensions and can, thus, be directly compared between films, 
cylinders, spheres and any other geometry of a drug delivery system, and this for arbitrary 
dimensions. 
 
3.1.4. Theoretical predictions for cylindrical extrudates 
Importantly, the knowledge of the dependence of the “apparent” drug diffusion 
coefficient of dexamethasone on the type of silicone, type and amount of optionally added 
PEG and initial drug loading can be used to theoretically predict the impact of the systems’ 
composition on the resulting drug release kinetics from arbitrarily sized and shaped silicone 
matrices. For instance, the diffusion coefficients of the drug determined with polymeric films 
(D) can be used to predict drug release from cylinders of varying dimensions. The dashed 
curves in Figure 3.12 show some examples for this type of in-silico simulations. In these 
cases, dexamethasone release from cylindrical extrudates based on different types of silicones, 
optionally exhibiting different dimensions, was theoretically predicted. In all cases, the drug 
loading was 10 % and the systems were PEG-free. The extrudates in Figures 3.12a and b were 
0.24 cm in diameter and 2.3 cm in length. They were based on MED-4735 (a) or 
MED-4055 (b), respectively. The extrudates in Figures 3.12c were 0.20 cm in diameter and 
3.2 cm in length, and based on MED-4065. The respective analytical solution of Fick’s 
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second law of diffusion for cylindrical geometry (considering the same initial and boundary 
conditions as those described above for the derivation of Eq. 1, which is valid for thin films) 
is as follows (136,138): 
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where Mt and M∞ represent the absolute cumulative amounts of dexamethasone released at 
time t and infinite time, respectively; qn are the roots of the Bessel function of the first kind of 
zero order [J0(qn)=0]; R and H denote the radius and height of the cylinder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Theoretical predictions (dashed curves, Eq. 2) and independent experiments 
(symbols): Dexamethasone release from cylindrical extrudates (10 % drug loading, no PEG) 
based on: a) MED-4735, b) MED-4055, c) MED-4065, and d) degree of sample saturation. 
The systems' dimensions are indicated in the diagrams. 
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The dashed curves in Figure 3.12 show the theoretical predictions made with Eq. 2, using 
the "apparent" dexamethasone diffusion coefficients determined with thin films. As it can be 
seen, the impact of the variations in the extrudates' dimensions and type of silicone on drug 
release was only minor. This is very interesting information when optimizing this type of 
controlled release dosage forms: Instead of performing long lasting release experiments, this 
knowledge becomes available within a few seconds (using a standard personal computer). In 
order to evaluate the reliability of these theoretical predictions, the respective cylinders were 
prepared in reality and the resulting dexamethasone release kinetics measured in practice 
(symbols in Figure 3.12). As it can be seen, good agreement between the theoretical 
predictions and independent experiments was observed in all cases. This demonstrates: (i) the 
reliability of the theoretical predictions, (ii) the potential practical benefit of such in-silico 
simulations to facilitate product optimization (which can for example avoid series of time-
consuming and cost-intensive trial-and-error studies), and (iii) the fact that diffusional mass 
transport seems to be also the dominant mass transport mechanism in cylindrical extrudates of 
the same composition. 
 
The knowledge presented in this chapter was used to adjust the drug release from liquid 
silicone rubber to prepare miniaturized Ear Cube implants that will be presented in the next 
section. The silicone LSR 5 was chosen to prepare those implants because of its relatively low 
viscosity and, thus, good injectability even at higher drug loadings (compared to the other 
silicones that were discussed in the present chapter). This plays a decisive role because the 
silicone - drug mixture has to be injected into customized molds. Furthermore, the workability 
time of silicone LSR 5 is sufficient to prepare the implant: The slow curing at room 
temperature does not interfere with the mixing, degassing and injection into the mold. 
Additionally, the drug release rate can easily be adjusted by changing the drug content of the 
silicone: The absolute drug release rate is increased with higher drug loadings. Overall, 
silicone LSR 5 provides ideal properties to prepare miniaturized Ear Cube implants loaded 
with dexamethasone. 
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3.2. Ear Cube implants for Controlled Drug Delivery to the Inner Ear 
Figure 2.1 shows schematically the design of the novel Ear Cube implants: On the left 
hand side, a "smaller" Ear Cube is shown, in the middle a "larger" one. The dimensions are 
indicated in mm. The cartoon on the right hand side illustrates how an Ear Cube can be placed 
into a hole drilled into (or close to) the oval window. The cylindrical part of the Ear Cube 
assures its fixation in (or close to) the oval window and is partially surrounded by perilymph. 
The cuboid is located in the middle ear. Importantly, the administration of such Ear Cubes is 
less invasive compared to the placement of intracochlear implants (which are entirely placed 
into the inner ear). At the same time, they allow for reliable controlled release into the inner 
ear (since they are fixed at or close to the oval window, in contrast to semi-solid formulations, 
which are placed without reliable fixation in the middle ear). If needed, a supplementary drop 
of spontaneously hardening silicone might be added onto the cuboid in vivo, to further assure 
its durable fixation on (or close to) the oval window. Drug transport into the cochlea is 
expected to occur: 1) through the cylindrical part of the Ear Cube, and 2) upon partitioning 
from the cuboid into the oval window, followed by diffusion through this membrane. 
 
3.2.1. Physico-chemical key properties of the Ear Cubes 
Macroscopic pictures of a "smaller" and a "larger" Ear Cube (loaded with 10 % 
dexamethasone) are shown in Figure 2.2 (at the bottom on the right hand side). As it can be 
seen, both implants appear to be homogeneous. The white color can serve as a first indication 
for the fact that the drug is not molecularly dispersed within the silicone (which is transparent 
without drug). Scanning electron microscopy pictures of cross-sections of an Ear Cube are 
shown in Figure 3.13. The scheme on the left hand side illustrates where the cross-sections 
were made: In the cylindrical parts of the implants. Clearly, tiny crystals are distributed 
throughout the silicone matrix. 
Figure 3.14 shows the DSC thermograms and X-ray diffraction patterns of a drug-free 
and a drug-loaded Ear Cube (10 % dexamethasone). For reasons of comparison, also 
dexamethasone powder (as received) was studied. As it can be seen, the latter was crystalline, 
exhibiting a melting peak at 263 °C and various sharp diffraction peaks. In contrast, drug-free 
Ear Cubes were X-ray amorphous and did not show any melting peak at 263 °C. Importantly, 
Ear Cubes loaded with 10 % dexamethasone showed a melting peak at that temperature and 
X-ray diffraction peaks at the same angles as the reference drug powder. Thus, the tiny 
crystals visible in the SEM pictures in Figure 3.13 are dexamethasone crystals. Interestingly, 
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the surfaces below the melting peaks in the DSC thermograms in Figure 3.14a allowed 
estimating that virtually the entire drug amount in the Ear Cubes is in the crystalline state. 
Thus, the presence of amorphous dexamethasone or dexamethasone dissolved in the silicone 
matrix is likely to be negligible. This is consistent with the fact that the glass transition 
temperature (Tg) of the silicone was not significantly altered upon drug incorporation (being 
in the range of -120 to -117 °C in drug-free and drug-loaded Ear Cubes). 
 
 
Figure 3.13. SEM pictures of cross-sections of an Ear Cube implant: The scheme on the left 
hand side illustrates where the cross-sections were made. The arrows mark tiny crystals. The 
drug loading was 10 %. 
 
 
 
 
Figure 3.14. a) DSC thermograms, and b) X-ray diffraction patterns of dexamethasone 
powder (as received), of a drug-free and of a drug-loaded Ear Cube implant 
(10 % dexamethasone). 
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3.2.2. Characterization of thin films of identical composition 
In order to determine the mobility of the drug in the investigated silicone matrices, thin 
films based on the same type of silicone (LSR 5) and loaded with different amounts of 
dexamethasone (10 to 40 %) were prepared and characterized. Also in these cases (and 
independent of the drug loading), the drug was virtually completely dispersed in the form of 
tiny crystals within the polymeric matrices, as evidenced for instance by the white (and 
homogeneous) color of the films (see for instance the picture on the left hand side at the 
bottom in Figure 2.2). The symbols Figure 3.15a show the experimentally measured release 
kinetics of dexamethasone (absolute amounts) from the thin silicone films into artificial 
perilymph at 37 °C. As it can be seen, the absolute release rate increased with increasing drug 
loading. Based on the hypothesis that dexamethasone diffusion through the polymeric matrix 
is the dominant mass transport step controlling drug release, the following analytical solution 
of Fick's second law can be used to quantitatively describe the drug release kinetics (137): 
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where Mt and M∞ denote the absolute cumulative amounts of drug released at time t and 
infinity, respectively; n is a dummy variable, D the “apparent” diffusion coefficient of the 
drug within the polymeric system; L represents the thickness of the film. 
 
It has to be pointed out that the silicone films did not swell or dissolve/erode to a 
noteworthy extend during the observation period. This is taken into account by Equation 1 (as 
well as a homogeneous initial drug distribution and sink conditions in the surrounding bulk 
fluid). In contrast, the model does not consider potential limited drug solubility effects within 
the silicone matrices. Since dexamethasone is distributed in the form of tiny crystals in the 
polymer and the amounts of water penetrating into the system upon exposure to the release 
medium are limited, it can be expected that not all the drug is rapidly dissolved in the matrix. 
Thus, dissolved and non-dissolved dexamethasone co-exist. Importantly, only dissolved drug 
is available for diffusion. Hence, when using Equation 1 to describe drug release from the 
investigated films, the diffusion coefficient (D) is likely to be a "lumped" parameter: It is not 
the "real" drug diffusivity in the investigated silicone matrices, but the "apparent" diffusion 
coefficient, which is biased by limited drug solubility effects (121). 
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Figure 3.15. Thin films: Impact of the drug loading (indicated in the diagrams) on the: 
a) absolute drug release rate, b) normalized relative drug release rate, c) “apparent” drug 
diffusion coefficient in the silicone matrix, and d) degree of saturation of the withdrawn 
samples. In a) and b), the symbols represent the experimental results, and the curves the fitted 
theory (Equation 1). 
 
Fitting Equation 1 to the experimentally determined dexamethasone release kinetics from 
thin silicone films loaded with 10 to 40 % drug resulted in good agreement in all cases (curves 
and symbols in Figure 3.15a). Thus, drug diffusion through the polymeric matrix seems to 
play an important role for the control of drug release. This knowledge allows normalizing 
drug release to the films' thicknesses: It has to be pointed out that arbitrary variations in the 
films' thickness can affect the resulting drug release kinetics (determining the lengths of the 
diffusion pathways, which need to be overcome). Consequently, some caution should be paid 
when comparing the results shown in Figure 3.15a: Not only the variation in the initial drug 
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loading might affect the release rates, but also unintended variations in the film thickness. 
Figure 3.15b shows the drug release kinetics, which were normalized to the films' thicknesses 
(and the total drug amounts). As it can be seen, the normalized relative drug release rates 
were rather similar in all cases (at least in the investigated observation periods): The relative 
release rate only slightly decreased with increasing initial drug loading (but caution should be 
paid, since the standard deviations were overlapping). 
Based on the fittings shown in Figures 3.15a and 3.15b, the "apparent" diffusion 
coefficient of dexamethasone in LSR 5 silicone could be determined in a quantitative way for 
the different drug loadings. As it can be seen in Figure 3.15c, the "apparent" D-values slightly 
decreased with increasing drug content (again, please note that the standard deviations are 
overlapping). This can serve as a further indication for the fact that limited drug solubility 
effects are playing a role in the investigated systems and that the D-values are lumped 
parameters. Note that outside of the silicone matrices (in the well stirred release medium 
surrounding the films) sink conditions were provided throughout the experiments, as 
illustrated in Figure 3.15d: The ratios "drug concentration in the withdrawn samples/drug 
solubility" are plotted as a function of time for the different initial drug loadings. 
To be able to determine the diffusion coefficient of dexamethasone in the investigated 
silicone without the bias of limited drug solubility effects within the polymeric matrix, 
another type of experiments was conducted: Thin, drug-free LSR 5 silicone films were 
prepared and dexamethasone diffusion through these films was measured in horizontal side-
by-side diffusion cells. The donor compartment was filled with artificial perilymph, which 
was saturated with the drug (and contained undissolved drug excess), whereas the acceptor 
compartment contained (initially) drug-free perilymph. Sink conditions were provided in the 
acceptor compartment throughout the experiment. The side-by-side diffusion cells were 
placed in a horizontal shaker (80 rpm) and kept at 37 °C. Figure 3.16 shows the 
experimentally determined cumulative amounts of drug that reached the acceptor 
compartment as a function of time (the blow-up zooms on early time points). As it can be 
seen, a straight line was observed (after a short lag time), indicating that steady state 
conditions were rapidly reached: The donor compartment remained saturated, the acceptor 
compartment provided sink conditions, and the films did not swell or dissolve/erode to a 
noteworthy extent. 
  
   RESULTS AND DISCUSSION 
66 
 
Under these conditions, the following equation can be used to describe drug transport 
through the silicone films: 
 
t
L
CKDAM st        (3) 
 
where Mt is the cumulative amount of drug transported at time t; A is the surface area of film 
available for diffusion in the diffusion cell; D is the diffusion coefficient of the drug within 
the film; K is the partition coefficient of the drug between the film and the bulk fluid; cs 
denotes the solubility of the drug in the bulk fluid, and L the thickness of the film. 
 
Importantly, the slope of the straight line in Figure 3.16 allows determining the product 
"drug diffusivity x partition coefficient". In the present case, D x K = 2.3 ± 0.2 x 10-10 was 
found. 
 
 
Figure 3.16. Side-by-side diffusion cells: Dexamethasone transport through thin (initially 
drug-free) silicone films. The blow-up zooms on early time points. 
 
Furthermore, the prolongation of the straight line allowed determining its intersection 
with the time-axis, which was found to be at t = 0.41 d. 
  
0
10
20
30
40
50
0 5 10 15 20
cu
m
u
la
tiv
e 
dr
ug
 tr
an
sp
or
te
d,
 
µg
time, d
0
2
4
6
8
0 1 2 3
   RESULTS AND DISCUSSION 
67 
 
Importantly, this value (together with the film's thickness) allows calculating the 
diffusion coefficient of the drug in the polymeric matrix without the bias of limited drug 
solubility effects, as follows: 
 
lagt
LD  6
2
      (4) 
 
where D is the diffusion coefficient of the drug within the film; L is the thickness of the film, 
and tlag is the lag time. 
 
In the present case, the diffusivity of dexamethasone in LSR 5 silicone was found to be 
equal to 1.9 ± 0.1 x 10-9 cm²/s. This is a significantly higher value compared to the "lumped" 
drug diffusivities determined by fitting Equation 1 to the experimentally determined drug 
release kinetics from thin films (Figure 3.15). The difference can mainly be attributed to the 
limited amounts of water present in the silicone films and the limited solubility of the drug. 
This should be kept in mind when using such "lumped" parameters. On the other hand, the 
determined "lumped" diffusivities much better take into the account the conditions in drug-
loaded silicone matrices (e.g., implants) compared to the "more realistic" drug diffusion 
coefficient determined with drug-free films: For instance, the impact of the initial drug 
loading on the “apparent” drug mobility in the polymeric matrix is not considered when 
conducting side-by-side diffusion cell experiments with drug-free films. Ideally, both types of 
experiments and appropriate theories should be conducted/applied (or the drug solubility 
within the silicone matrix during drug release should be known). In any case, all assumptions 
a specific mathematical model is based on, should be considered. And caution should be paid, 
if certain processes are "lumped", or not taken into account. From a practical point of view, it 
might not harm if “lumped” parameters are used to estimate the impact of formulation 
parameters on drug release. In contrast, it might reduce the workload, since the knowledge of 
certain parameters (e.g. the drug solubility within the polymeric matrix during drug release) is 
not mandatory. 
 
3.2.3. Drug release from Ear Cubes 
Importantly, knowing the “apparent” drug diffusion coefficient of dexamethasone in the 
investigated silicone matrices, the resulting drug release rates from Ear Cubes can be 
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theoretically predicted. In the present case, the "apparent" dexamethasone diffusivity in 
LSR 5 silicone matrices containing 10 to 30 % drug was used to predict the release rates from 
"smaller" and "larger" Ear Cubes (Figure 2.1) (note that implants loaded with 40 % 
dexamethasone were difficult to prepare, due to the high viscosity of the “drug-silicone 
preparation kit” blend). Since only the very early drug release phases were experimentally 
measured in this study (< 1 % of the total drug amount was released during the first 
2 months), the applied theory only considered dexamethasone release from the cylindrical 
parts of the Ear Cubes (highlighted in the schemes in Figure 3.17). Two different equations 
were applied: 
 
1) An analytical solution of Fick's law of diffusion considering dexamethasone release 
through all surfaces of the cylinders (scheme on the left hand side of Figure 3.17) (137): 
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where Mt and M∞ represent the absolute cumulative amounts of dexamethasone released at 
time t and infinite time, respectively; n and q denote dummy variables; qn are the roots of the 
Bessel function of the first kind of zero order [J0(qn)=0]; R and H denote the radius and 
height of the cylinder. 
 
2) An analytical solution of Fick's law of diffusion considering dexamethasone release 
only through the circular surface at the bottom the cylinders (scheme on the right hand side of 
Figure 3.17) (137): 
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where Mt and M∞ represent the absolute cumulative amounts of drug released at time t, and 
infinite time, respectively; n is a dummy variable, and H the height of the cylinder. 
 
Equation 2 likely overestimates drug release, because the upper circular surface of the 
cylinders is not available for drug release and it is uncertain whether all the other cylinder 
surfaces are fully wetted and available for drug release. On the other hand side, Equation 5 
likely underestimates dexamethasone release, since drug release is probably not fully 
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restricted to only the bottom circular surface of the cylinders. A more comprehensive 
mathematical model could be used to more precisely quantify drug release from the given 
geometries, but the reliability of such predictions remains questionable, because of the 
uncertainty which parts of the surfaces are effectively wetted. In this study, the aim was only 
to roughly estimate the amounts of drug released from the Ear Cubes at “very early” time 
points. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17. Schematic presentation of the geometries and directions of drug diffusion 
considered in Equation 2 (left hand side) and Equation 5 (right hand side) in order to estimate 
dexamethasone release from Ear Cubes at very early time points. Details are given in the text.  
 
The curves in Figure 3.18 show the theoretically predicted dexamethasone release 
kinetics from a "smaller" and a "larger" Ear Cube, loaded with 10 to 30 % drug. The 
green/orange/red colors correspond to implants loaded with 10/20/30 % dexamethasone, 
respectively. The solid curves were calculated using Equation 2 and likely overestimate drug 
release, while the dashed curves were calculated using Equation 5 and likely underestimate 
drug release (for the reasons discussed above). The left column shows the relative drug 
release rates, the middle column the absolute release rates. As it can be seen, the predicted 
relative drug release rates decrease with increasing initial dexamethasone loading, whereas 
the predicted absolute drug release rates increase with increasing initial drug content. The first 
tendency can be explained by the decrease in the "apparent" drug diffusivity with increasing 
dexamethasone loading (Figure 3.15c) (due to the increasing importance of limited drug 
solubility effects). The second tendency is due to the increasing drug concentration gradients 
(since all drug is considered to be rapidly dissolved upon exposure to the release medium), 
and the increasing matrix porosity upon drug exhaust with increasing initial drug content. If 
these rough estimations are correct, the cumulative amounts of dexamethasone released from 
the Ear Cubes should be in the range of 0.06 to 1.45 %, or 0.046 to 2.35 µg after 2 months. 
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Thus, drug release can be expected to be controlled during several years in vivo (which can be 
highly desirable, avoiding additional surgeries). When comparing the "smaller" and "larger" 
Ear Cubes (top versus bottom row in Figure 3.18), it becomes evident that the (relative and 
absolute) dexamethasone release rates are expected to be higher from "smaller" Ear Cubes, 
irrespective of the initial drug loading. This is due to the fact that the "smaller" Ear Cubes 
have a longer cylindrical part than the "larger" Ear Cubes (Figure 2.1), and that drug release at 
these early time points is considered to be limited to this part of the implants. 
 
 
Figure 3.18. Dexamethasone release from Ear Cubes (top row: smaller Ear Cubes, bottom 
row: larger Ear Cubes): Impact of the initial drug loading (indicated in the diagrams). The 
relative and absolute release rates as well as the degree of saturation of the withdrawn samples 
are illustrated (left, middle and right column). The symbols represent the experimental results. 
The solid curves indicate the theoretically predicted drug release kinetics using Equation 2, 
while the dashed curves represent the theoretically predicted release kinetics using Equation 
5. The drug loading was 10, 20 and 30 % (corresponding to green, orange and red symbols, 
curves and bars).  
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In order to evaluate the reliability of the theoretical predictions, "smaller" and "larger" 
Ear Cubes loaded with 10 to 30 % dexamethasone were prepared in reality and drug release 
was measured using the experimental setup illustrated in Figure 2.3. The green, orange and 
red symbols in Figure 3.18 show the respective experimental results. As it can be seen, most 
of the independent experimental results were located within the theoretically predicted ranges. 
Thus, the basic hypothesis that dexamethasone release is predominantly controlled by 
diffusion through the silicone matrices (and limited drug solubility effects) seems to be 
realistic. The expected impact of the initial drug loading on the resulting absolute drug release 
rates was confirmed for both types of Ear Cubes, while the differences with respect to the 
relative drug release rates were within the orders of magnitude of the experimental errors. It 
has to be pointed out that in vivo the drug can also be expected to diffuse from the cuboid into 
the oval window and cross this membrane. This mass transport way was not simulated in the 
experimental set-up. Thus, in vivo drug release is likely to be somewhat faster, but is still 
likely to be sustained during several years. The right column in Figure 3.18 shows the 
experimentally measured degree of drug saturation in the withdrawn samples, as a function of 
time and initial drug loading. As it can be seen, sink conditions were provided, irrespective of 
the initial drug loading, sampling time point and type of Ear Cube. 
 
3.2.4. Absence of Ear Cube swelling 
Another very important practical aspect for the newly proposed Ear Cubes is their 
swelling behavior upon exposure to aqueous media. Significant swelling could cause tissue 
irritation/damage due to the tiny dimensions of the cochlea, oval window and middle ear. In 
addition, the anchorage in (or close to) the oval window might be compromised. For these 
reasons, potential changes in the Ear Cubes’ dimensions were monitored upon exposure to 
artificial perilymph at 37 °C. Figure 3.19 shows macroscopic pictures of a "smaller" (top row) 
and a "larger" (bottom row) Ear Cube before exposure to the release medium and after 14 and 
60 d, respectively. Also, the two diagrams at the bottom of Figure 3.19 illustrate the dynamic 
changes in the Ear Cubes' dimensions as a function of time. Clearly, the geometries and sizes 
of the Ear Cubes remained about constant: No noteworthy swelling was observed. This is very 
important from a practical point of view. 
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Figure 3.19. Absence of Ear Cube swellingμ Macroscopic pictures (top rowμ “smaller” Ear 
Cubes, bottom rowμ “larger” Ear Cubes), and "dimensions versus time" plots. The initial drug 
loading was 10 %. Details are given in the text.  
 
 
In the next chapter, a new type of in situ forming implant releasing dexamethasone 
beside the stapes’ footplate will be presented. This in situ formed implant is inspired by in situ 
forming gels that are already used in clinical trials to deliver drugs to the inner ear (as 
described in section 1.3.2.1 Intratympanic drug delivery). The system of an in situ forming 
silicone-based implant is promising because it can easily be injected into the middle ear cavity 
and is curing directly in vivo. Another advantage is that the shape of the implant adapts 
perfectly to the patient’s individual anatomy. Patients could benefit from this adaptable 
system since the anatomy of the middle ear cavity can differ to a big extend from one patient 
to another. 
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To prepare this new in situ forming implant, another type of silicone has to be tested. The 
silicone should be easily injectable on one hand. On the other hand, the polymer has to cure 
relatively fast in vivo because otherwise it could be eliminated through the Eustachian tube. 
To increase the drug release from the implant, the hydrophilic excipient PEG 400 was added 
to the formulation. 
.  
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3.3. Trans-Oval-Window Implants: Extended Dexamethasone Release 
3.3.1. Results 
3.3.1.1. In vitro studies 
Dexamethasone Release From Silicone-based Films 
As it can be seen (Figure 3.20), the drug release rate decreased with time from thin films 
based on Kwik-Cast silicone. Drug release was prolonged and continuous during the 
observation period (30 days). Importantly, drug saturation effects were not affecting 
dexamethasone release to a noteworthy extent. 
 
 
Figure 3.20. Dexamethasone release from thin films based on Kwik-Cast silicone, loaded 
with 10 % drug and 5 % PEG 400 in 10 mL artificial perilymph: a) relative drug release, 
b) absolute drug release, and c) degree of drug saturation of the withdrawn samples. The 
symbols represent the experimental results, the curves the fitted theory (Equation 1). 
 
Fitting the following analytical solution of Fick’s second law of diffusion (137) to the 
experimental results resulted in good agreement between theory (curves) and experiments 
(symbols) (Figure 3.20a and b): 
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where Mt and M∞ denote the absolute cumulative amounts of drug released at time t and 
infinity, respectively; n is a dummy variable, D the “apparent” diffusion coefficient of the 
drug within the polymeric system; L represents the thickness of the film. 
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Thus, drug diffusion through the polymeric matrix seems to play a major role for the 
control of dexamethasone release. Based on these calculations, the following apparent 
dexamethasone diffusion coefficient in the investigated Kwik-Cast silicone-PEG matrix could 
be determined: D = 1.2 x 10-11 cm2/s. 
 
Dexamethasone Release From Silicone-based Implants 
As in the case of the thin films, the drug release rate from Silicone-based implants 
decreased with time and sink conditions were maintained during the observation period 
(Figure 3.21). It has to be pointed out that dexamethasone release was much slower from the 
implants compared to the films (Figure 3.21 vs. Figure 3.20). This can at least partially be 
attributed to the much lower surface area exposed to the release medium in relation to the 
total system’s volume. 
 
Figure 3.21. Dexamethasone release from miniaturized implants loaded with 10 % drug and 
5 % PEG 400 into 100 mL artificial perilymph: a) Relative drug release, b) absolute drug 
release, and c) degree of drug saturation of the withdrawn samples. 
 
3.3.1.2. In vivo studies 
Implantation 
The chosen silicone for implantation was Kwik-Cast, loaded with 10 % dexamethasone 
and 5 % PEG 400. Drug crystals can be observed by Confocal Laser Scanning Microscopy 
(CLSM). The drug was dispersed in the form of small particles in the matrix and was not 
completely dissolved (Figure 3.22). Twelve gerbils were implanted bilaterally by a 
submandibular approach.  
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Figure 3.22. Thin silicone film loaded with 10% dexamethasone and 5% PEG 400 observed 
with CLSM (scale bar =100 µm). 
 
Confocal Microscopy 
Confocal imaging allowed a morphometric and threedimensional analysis of the whole 
cochlea. DAPI and Phalloidin enabled a fluorescent labeling of the nucleus and the 
cytoskeleton of the cell, respectively. 
Because the structure of the cochlea has been preserved during the immunohistochemical 
treatment, the entire architecture with the three turns of the cochlea can be clearly seen 
(Figure 3.23A). 
 
 
Figure 3.23. A) Maximum intensity projection of a whole cochlea after implantation with 
CLSM: Maximum intensity projection of a medial view upon treatment with Phalloidin (for 
actin cytoskeleton labeling). Three turns of the cochlea can be seen: the apical, middle, and 
basal turn (scale bar = 50 µm, objective x 10). B) Maximum intensity projections of cochlea 
of gerbils receiving the novel implant: Transapical views of the middle turn of the whole 
cochlea of animals sacrificed on day 7 by CLSM (objective x 10, scale bar = 50 µm). 
Labeling of cell nuclei with DAPI (D), actin cytoskeleton with phalloidin (P), dexamethasone 
(DXM). All three labelings are superposed in the fourth picture of each series (A). 
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By turning the image during the three-dimensional acquisition, the middle turn of cochlea 
with the three rows of outer hair cells and one row of inner hair cells seemed to be intact after 
implantation (Figure 3.24). 
 
 
 
Figure 3.24. Maximum intensity projections. A) Middle turn of a whole cochlea after 
implantation (medial three-dimensional view) (objective x 10). B) Three rows of outer hair 
cells and one row of inner hair cells in the middle turn of the cochlea with CLSM (scale 
bar = 20 µm, objective x 20). The red labeling (with phalloidin) visualizes actin cytoskeleton, 
the blue labeling (with DAPI) cell nuclei. 
 
Confocal imaging of cochlea sections enabled to validate the specificity of anti-
dexamethasone immunolabeling compared with controls wherein the green fluorescence was 
absent (Figure 3.25). 
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Figure 3.25. Cochlea sections taken A) after intratympanic injection of a solution of 
dexamethasone, immunolabeling with primary and secondary antibodies, B) after 
intratympanic injection of a solution of dexamethasone, immunolabeling with secondary 
antibody only, and C) on untreated ear, immunolabeling with primary and secondary 
antibodies (scale bar = 20 µm, objective x 10). Labeling of cell nuclei with DAPI (D), actin 
cytoskeleton with phalloidin (P), dexamethasone (DXM). All three labelings are superposed 
in the fourth picture of each series (A).  
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Imaging of the whole cochlea, confirmed the absence of autofluorescence or nonspecific 
staining (Figure 3.26). 
 
Figure 3.26. Transapical view of the middle turn of the cochlea in CLSM. A) Cochlea after 
intratympanic injection of a solution, and B) Untreated cochlea. In both cases labeling with 
primary and secondary antibodies (scale bar = 20 µm, objective x 10). Labeling of actin 
cytoskeleton with phalloidin (P) and dexamethasone (DXM). 
 
Images of whole cochleae also allowed the detection of specific anti-dexamethasone 
fluorescence in the hair cells. Interestingly, this immunolabeling was detected in hair cells of 
all implanted cochleae (protocol as described in the section Immunohistochemistry). The 
staining intensity reached a climax for the cochlea collected at day 7 postimplantation 
(Figures 3.23B and 3.27B). For these experiments, the same parameters for the laser intensity 
and the voltage of the detector were used to compare intensity between the different 
conditions. 
Surprisingly, the anti-dexamethasone labeling could be already detected inside the hair 
cells 20 min postimplantation and even at day 30 the labeling was still observed (Figure 3.27). 
The detection at very early time points might be attributable to rapid dexamethasone release 
from the (still liquid) formulations right upon injection and/or drug diffusion occurring during 
sample preparation. 
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Specific fluorescence imaging of the organ of Corti allowed to localize the 
immunostaining directly inside the hair cells (Figure 3.28A–C). Anti-dexamethasone labeling 
was present mainly in the cell body and not in the cell nucleus (Figure 3.28C–E). 
 
 
 
Figure 3.27. Snapshot of a transapical view of the middle turn of the whole cochlea by 
CLSM. Cochlea collected at A) day 0, B) day 7, and C) day 30, after implantation (scale 
bar = 50 µm, objective x 10). Labeling of dexamethasone (DXM) with anti-dexamethasone 
antibodies and actin cytoskeleton with phalloidin (P). 
 
3.3.2. Discussion 
Silicone was chosen as a polymer for its properties of biocompatibility, biodurability, 
chemical-thermal stability and lack of toxicity. It is already used in many medical applications 
(139) in humans. Cochlear implantation was especially established as a safe and effective 
method for the rehabilitation of patients with profound hearing loss (140). Recently, the 
development of an electrode array, from MED-4735 silicone, with prolonged release of 
dexamethasone was reported as part of preservation of residual hearing after cochlear 
implantation (103,104). 
Several researchers are interested in the use of resorbable biopolymers for drug release in 
the round window: gelatin (141), polylactide-co-glycolide (142), chitosan glycerol phosphate 
(96). The main disadvantage of these polymers is the limited amount of drug that could be 
incorporated into the matrix and formed to a particular shape (143). In adition, the quick 
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release and degradation of these matrixes are not suitable for the treatment of chronic 
pathologies. 
 
Figure 3.28. Maximum intensity projection of organ of Corti after implantation. View of 
three rows of outer hair cells (layered) and one row of inner hair cells by CLSM (A, B, C). 
Location of specific labeling in inner hair cells and outer hair cells (scale bar = 20 µm, 
objective x 20). Snapshot of organ of Corti after implantation (D, E, F). View of one row of 
outer hair cells and one row of inner hair cells with CLSM (D, E, F). Visualization of cell 
bodies, cell nuclei, and stereocils. Location of specific labeling (green) in cell body (scale 
bar = 20 µm, objective x 63). A and D, Labeling with phalloidin (red) and DAPI (blue); B and 
E, labeling with anti-DXM antibodies (green) and DAPI (blue); C and F, labeling with 
phalloidin (red), DAPI (blue), and anti-dexamethasone antibodies (green). N = cell nucleus; 
B = cell body; S = stereocil; OHC = outer hair cell; IHC = inner hair cell. 
 
The Mongolian gerbil was chosen as experimental model because this animal, commonly 
used in otologic research, has a superficial auditory bulla and an auditory spectrum similar to 
humans (144). Indeed, several experimental studies focused on preservation of residual 
hearing after cochlear implantation (103,145). 
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Surgery had to be cautious since the stapedial artery passes between the crus of the 
stapes. One gerbil died from massive bleeding after a stapedial artery injury. In humans, the 
stapedial artery is an embryonic artery that atrophies normally around the 10th week in utero. 
Unlike humans, it persists in many animals, particularly rodents including gerbils (146). 
Given these anatomical animal characteristics, the site of implantation in this study, originally 
planned on the footplate of stapes, was changed for the lateral side of the oval window. 
Carrying out acquisitions of a gerbil cochlea in confocal microscopy was very 
challenging due to their geometry and complex architecture, the superposition of the 
structures, the inhomogeneity of the tissues, and the time consuming process of cochlea 
clarification (147). 
The cochlea is one of the densest organs in the human body. The protocol of clarification 
that has been used (148) turned the entire cochlea transparent. Seven days were required to 
decalcify the cochlea of the gerbils entirely, versus only 4 days required for the cochlea of 
mice (147). 
Many studies were performed on sectional tissues (149) or on mounted organs of Corti 
(150). This strategy reduces or suppresses the time needed for clarification but does not allow 
to preserve the overall cochlear architecture. 
In a recent study, the intensity of immunostaining reached a maximum at 1 h, then 
decreased at 6 and 12 h after corticosteroid intratympanic injection. Additionally, there was a 
more important uptake of the dexamethasone by the inner hair cells compared to outer hair 
cells (149). 
In this study, the specific dexamethasone labeling was detected in the inner ear at day 0, 
day 7, and day 30 postimplantation. The labeling was more intense at day 7, this could be in 
connection with the initially higher release rate of dexamethasone observed in vitro at early 
time points. The affinity for dexamethasone seemed to be the same for inner hair cells and 
outer hair cells and there was a main uptake of drug by cell bodies of hair cells. 
In the short term, we would like to optimize the creation of implants to make their size 
reproducible. We will also use acoustic trauma experimental model and auditory brainstem 
response to evaluate effectiveness of our implants on hearing preservation. In the long term, 
this new strategy of local treatment could be useful, in humans, in sudden sensorineural 
hearing loss, tinnitus, autoimmune disease, and ototoxic hearing loss. 
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4. Conclusion 
Today, the therapy of hearing loss is a challenge due to the vast variety of etiologies that 
in most of the cases remain unknown. Different therapies are currently under development 
mainly focusing on local controlled drug delivery to the inner ear. The major difficulties are 
the small dimensions of the system as well as the sensibility of the inner ear hair cells. 
Miniaturized implants might provide a suitable therapy for patients suffering from hearing 
loss. In this thesis, two different types of silicone-based implants, releasing dexamethasone 
for a prolonged period that can be implanted at the stapes’ footplate have been developed and 
characterized. 
In the introduction, the anatomy and physiology of the inner ear as well as its barriers 
were summarized, including an explanation on the function of the auditory perception and the 
sense of balance. Subsequently, diseases of the inner ear have been described focusing on 
hearing loss. Furthermore, different strategies for the treatment of hearing loss have been 
reviewed describing intratympanic and intracochlear drug delivery approaches. 
In the first section of the results, it has been proofed that different formulation 
parameters, such as the type of silicone, addition of varying amounts and types of PEG as 
well as the initial drug loading can be used to adjust desired drug mobility in controlled 
release silicone matrices. Importantly, often diffusional mass transport is decisive for the 
control of drug release. Thus, the “apparent” diffusion coefficient of the drug within the 
system can be used to: (i) quantify the effects of the formulation parameters, and 
(ii) theoretically predict drug release from dosage forms of arbitrary geometry and 
dimensions. Hence, time-consuming and cost-intensive series of trial-and-error experiments 
can be replaced by in-silico simulations. This is particularly helpful, if long-term drug release 
(e.g. during several weeks, months or years) is targeted. 
This knowledge has been used to prepare silicone-based implants described in the second 
section: The newly proposed Ear Cubes offer an interesting potential for local controlled drug 
delivery to the inner ear: They can control drug release during long periods of time, can be 
securely fixed at (or close to) the oval window and their placement is less invasive compared 
to intracochlear implants. They could also be placed into tiny holes drilled into the round 
window.  
A second type of silicone-based implants is presented in the third part: A new in situ 
forming device for local drug delivery to the inner ear using a non-degradable polymeric 
silicone matrix has been developed. The in vitro study of dexamethasone demonstrated a 
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continuous and prolonged release from dexamethasone-loaded implants for at least 90 days. 
After implantation of gerbils near the stapes’ footplate, corticosteroid detection inside the hair 
cells by cochlear confocal microscopy proves the effectiveness of dexamethasone-loaded 
implants as a targeted strategy for controlled release to the inner ear. This type of implant 
could also be used as carrier for other therapies. 
Future studies should address the in vivo efficacy (e.g., reduction of hearing loss due to 
acoustic trauma) and suitability to delivery other types of drugs than dexamethasone (e.g., 
gentamicin, adenovirus, eukaryotic vectors). 
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Résumé 
1. Sujet de recherche et son contexte scientifique 
 
L’oreille interne est l’organe responsable de la perception auditive et le maintien de 
l’équilibre. L’OMS estime que 360 millions personnes dans le monde (plus que 5 % de la 
population) souffrent d’une perte auditive handicapante, soit 40 dB dans l’oreille qui entend le 
mieux. L’impact sur la vie personnelle ainsi que professionnelle est considérable : Dans 
certaines sociétés les patients sont stigmatisés ou partiellement exclus du système éducatif. Ils 
ont beaucoup plus de mal à accéder au monde du travail et, par conséquence, cela impacte 
leur niveau de pauvreté. 
 
L’anatomie et physiologie de l’oreille 
Afin de comprendre les différentes stratégies permettant de traiter la surdité et les autres 
maladies de l’oreille interne, l’anatomie et la physiologie de l’oreille vont brièvement être 
présentées. 
L’oreille peut être divisée en trois parties μ (i) l’oreille externe avec l’auricule et le 
conduit auditif externe. Le tympan sépare cette partie de (ii) l’oreille moyenne qui contient la 
chaîne ossiculaire (le marteau, l’enclume et l’étrier) et le trompe d’eustache qui lie l’oreille 
moyenne au rhinopharynx et sert à équilibrer les différences de pression. La fenêtre ovale et la 
fenêtre ronde sont des membranes semi-perméables qui lient l’oreille moyenne avec l’oreille 
interne. (iii) L’oreille interne consiste de deux parties : la cochlée et le système vestibulaire.  
Dans la cochlée saine, une onde sonore est transformée en signaux mécaniques. La 
perception auditive se fait en plusieurs étapes μ Le son arrive à l’auricule de l’oreille externe et 
est canalisé et transmis pour faire vibrer le tympan. Cette vibration est amplifiée par la chaîne 
ossiculaire qui fait vibrer la fenêtre ovale. Par conséquence, les différents espaces liquidiens 
de l’oreille interne sont déplacés. Ces signaux font balancer des cellules ciliées en fonction de 
la fréquence et de l’amplitude du signal original. Le mouvement des cellules ciliées induit un 
signal électrique qui est transformé en perception sensorielle dans le cerveau. 
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La perception de la position de la tête et de son accélération est la fonction principale du 
système vestibulaire de l’oreille interne. Le mouvement de la tête induit un déplacement de 
liquide dans les canaux semi-circulaires dans la direction opposée. Par conséquent, les 
cellules ciliées du système vestibulaire balancent. Ce signal est ensuite traduit en signal 
électrique et transmis au cerveau pour assurer l’équilibre du corps. 
Quand ces systèmes de perception sont perturbés ou endommagés, différentes maladies 
de l’oreille interne peuvent se manifester, ex : la surdité, les acouphènes, les réactions 
auto-immunes de l’oreille interne et la maladie de Menière. Souvent, en clinique un mélange 
des différentes maladies est observé. 
 
La surdité 
La surdité est une maladie qui peut être très effrayante pour le patient, particulièrement 
quand elle apparaît brusquement. En plus de la surdité, les patients peuvent ressentir un 
épisode d’acouphènes, de vertiges ou autres symptômes. 
La surdité peut se présenter sous une forme périnatale ou elle peut être acquise au cours 
de la vie. Les causes qui mènent à la surdité sont diverses : On différencie les réactions auto-
immunes, physiques et chimiques. Les effets physiques peuvent être le résultat d’une 
exposition à un bruit aigu ou régulier (traumatisme sonore), l’irradiation de la gorge et de la 
tête lors d’une radiothérapie ou un traumatisme au cours d’une intervention chirurgicale. Les 
effets chimiques à l’origine d’une surdité, peuvent quant à eux être provoqués par des 
antibiotiques ototoxiques ainsi qu’une chimiothérapie anticancéreuse. De plus, une infection 
virale ou un évènement vasculaire peuvent être à l’origine de surdités brusques. La surdité 
peut aussi résulter d’une réaction auto-immune déficitaire. Par conséquent, les cellules ciliées 
peuvent être endommagées, une dégénération de la stria vascularis ou une perte de cellules du 
ganglion spiral peut se produire. La dimension et la réversibilité de la maladie dépendent 
fortement de la cause de la surdité. Malheureusement, dans la majorité des cas, la cause de la 
maladie reste incertaine. 
Le traitement est aussi relié à la cause de la maladie. Si celle-ci est connue, le patient est 
traité en conséquence. Sinon, le patient reçoit souvent des stéroïdes par voie orale ou 
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intra-tympaniques. Ces stéroïdes sont utilisés pour prévenir les inflammations ou œdèmes 
pouvant endommager les très sensibles cellules ciliées de l’oreille interne. D’autres stratégies 
incluent l’administration orale de principes actifs antiviraux, de diurétiques, de 
vasodilatateurs, d’antioxydants, un traitement avec de l’oxygène hyperbare ou des traitements 
chirurgicaux de l’oreille. L’application d’un appareil auditif tel que l’implantation d’un 
implant cochléaire peut être nécessaire si la surdité persiste. Un implant cochléaire transforme 
de la même façon que les cellules ciliées un son en signal électrique qui peut être retraduit en 
perception auditive dans le cerveau. L’électrode est reliée à un amplificateur implanté derrière 
l’oreille du patient. L’implantation d’une électrode dans la scala tympani de l’oreille interne 
peut alors aider à reconstituer la perception sensorielle. 
 
Libération de principes actifs à l’oreille interne 
L’administration d’un principe actif dans l’oreille interne constitue un véritable challenge 
de par la barrière hémato-cochléaire qui est comparable à la barrière hémato-encéphalique et 
protège l’oreille de substances toxiques. L’administration d’un principe actif par les voies 
classiques (orale, intraveineuse, intramusculaire) ne permet pas d’atteindre  des 
concentrations suffisantes au niveau de l’oreille interne pour traiter une maladie. Les jonctions 
serrées de la barrière hémato-cochléaire peuvent être contournées par un dosage systémique 
très élevé du principe actif. Une dose élevée de dexaméthasone peut par exemple être une 
bonne prévention contre la perte de perception auditive lors de l’insertion d’un implant 
cochléaire. Cependant, un dosage systémique élevé peut mener à des effets secondaires très 
graves. De la même façon, l’injection locale dans l’oreille interne d’un principe actif ne 
semble pas favorable car la solution peut s’écouler par le canal d’injection. De plus, pour le 
traitement d’une maladie chronique plusieurs injections sont nécessaires, augmentant le risque 
d’infection. La cochlée, est relativement étanche et extrêmement sensible aux changements 
mineurs de pression et représente donc un espace assez délicat avec un volume très faible.  
C’est pourquoi, une administration locale et unique peut fournir de grands avantages. 
Plusieurs possibilités pour une administration prolongée ont été décrites. L’application d’un 
hydrogel semi-solide sur la fenêtre ronde peut créer une matrice qui libère le principe actif 
d’une manière prolongée. Par contre, le gel ne pouvant pas être fixé in vivo, il risque d’être 
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éliminé très rapidement. En outre, le temps d’exposition et l’anatomie de la fenêtre ronde peut 
varier d’un patient à l’autre. De plus, la périlymphe (fluide principal dans la cochlée) peut être 
considérée comme un fluide non-agité avec un transport de masse négligeable. Par 
conséquence, un principe actif administré dans l’oreille moyenne risque de ne pas être 
distribué de manière homogène dans la périlymphe de l’oreille interne. D’un point de vue 
clinique,  un autre obstacle doit être surmonté: la taille minuscule de la cochlée et sa difficulté 
anatomique d’accès.  
Pour un traitement à long terme une libération à partir d’implants miniaturisés semble 
prometteuse : Créer des implants cubiques avec un cylindre peut donc aider à franchir toutes 
les restrictions mentionnées ci-dessus. L’implant étant partiellement inséré sur (ou à côté de) 
la fenêtre ovale, il permet de libérer le PA de manière contrôlée pendant des mois ou des 
années. Néanmoins, cette intervention est relativement invasive et le bénéfice pour chaque 
patient doit être évalué en détail. 
Cet implant pourra consister d’une matrice polymérique, notamment à base de silicone à 
cause de ses excellentes propriétés mécaniques et son innocuité.  
 
La mobilité de la dexaméthasone dans une matrice de silicone 
Le silicone chargé en principe actif n’est pas seulement utilisé pour traiter les maladies 
de l’oreille interne, par exemple à partir des électrodes d’un implant cochléaire chargé en 
dexaméthasone, mais aussi pour traiter des pathologies très diverses telles que le traitement de 
maladies du vagin, du cœur, de l’œil ou pour améliorer la cicatrisation. 
La libération de principe actif à partir de silicone peut être maintenue pendant des 
années : Du silicone chargé en dexaméthasone a été implanté avec succès dans des 
pacemakers. Après 10 ans d’implantation, une amélioration du fonctionnement de l’électrode 
est observée comparativement aux pacemakers non chargés en principe actif. 
Pour ajuster la libération du principe actif, plusieurs paramètres peuvent être variés tels 
que le type de chaînes latérales, l’ajout d’additifs, ou encore le taux de principe actif. De plus, 
la géométrie et les dimensions du système peuvent avoir une grande influence sur la libération 
car ils impactent la longueur du « trajet » à parcourir par le principe actif pour être libéré. Ceci 
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est d’autant plus important de par la nature plutôt hydrophobe du polymère ralentissant la 
pénétration de l’eau dans la matrice et par conséquent la libération du principe actif. L’ajout 
d’additifs hydrophiles, comme le polyéthylène glycol, facilite la pénétration de l’eau et donc 
la libération du principe actif. 
 
Objectif de recherche 
L’objectif de ces travaux était de développer de nouveaux implants miniaturisés pour le 
traitement de maladies telles que la surdité et les acouphènes. Les systèmes sont basés sur le 
silicone, un polymère biocompatible, chargé en dexaméthasone pour la libération contrôlée de 
dexaméthasone dans l’oreille interne.  
Les principaux objectifs de cette thèse incluent : 
(i) La préparation et la caractérisation des matrices chargés en principe actif in 
vitro afin d’identifier des outils simples pour ajuster le taux de libération. Plusieurs 
paramètres de formulation ont été évalués : Le taux de polyéthylène glycol ajouté ainsi 
que la variation du poids moléculaire de ce dernier. De plus, la structure chimique du 
silicone et son taux initial ont été varié. Les mécanismes de libération ont été élucidés 
par modélisation mathématique. 
 
(ii) Conception d’implants chargés en dexaméthasone en utilisant le silicone le 
plus prometteur. Préparation des films et des implants pour les caractériser in vitro. 
 
(iii) Conception d’implants se formant in situ chargés en dexaméthasone en 
utilisant le silicone le plus prometteur. Préparation des films et des implants pour les 
caractériser in vitro. La formulation a également été évaluée in vivo en se basant sur un 
modèle de gerbilles. Le principe actif a été détecté dans la cochlée explantée par 
microscopie confocale laser. 
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2. Matériels et méthodes 
Préparation des matrices chargées en dexaméthasone : 
Films - Silicone pâteux 
Les Partie A et B du kit de silicone ont été mélangées séparément puis réunies dans un 
laminoir (Chef Premier KMC 560/AT970A, Kenwood, Havant, UK). Le principe actif a été 
introduit petit à petit dans les parties A et B afin d’éviter toute perte. La masse a été mélangée 
jusqu’à obtenir un mélange homogène. La masse ainsi obtenue a été introduite entre deux 
couches de Teflon pour ajuster l’épaisseur du film lors de son passage dans le laminoir. La 
réticulation a été effectuée dans une étuve à 60 °C pendant 24 h.  
Films - Silicone liquide 
Les Partie A et B du kit de silicone ont été mélangées dans un mortier refroidi par des 
glaçons (pour ralentir la réticulation). Le principe actif a été introduit petit à petit dans les 
parties A et B afin d’éviter toute perte. La masse a été mélangée jusqu’à obtenir un mélange 
homogène. La masse ainsi obtenue a été introduite entre deux couches de Teflon pour ajuster 
l’épaisseur du film lors de son passage dans le laminoir. La réticulation a été effectuée dans 
une étuve à 60 °C pendant 24 h. 
Pour la préparation des films chargés à la fois en dexaméthasone et en polyéthylène 
glycol (PEG), le PEG était préalablement mélangé avec le principe actif avant d’introduire ce 
mélange PEG-dexaméthasone dans le silicone comme décrit ci-dessus. 
Les films sans principe actif étaient préparés en conséquence sans ajout de 
dexaméthasone. 
Implants « Ear Cube » 
Le mélange silicone liquide-dexaméthasone a été préparé comme décrit ci-dessus et mis 
en seringue et injecté dans le moule à implants. Après réticulation des implants à 60 °C, les 
implants ont été démoulés précautionneusement sous macroscope. 
Implants se formant in situ 
Le mélange PEG-dexaméthasone a été introduit séparément dans les partie A et B du kit 
de silicone, puis introduit séparément dans une double seringue pour éviter la réticulation 
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rapide du silicone intervenant par contact entre les 2 parties du silicone. L’implant s’est formé 
in situ après mélange des deux composants à température ambiante ou in vivo. 
 
Caractérisation in vitro : 
 Etudes de libération 
Les cinétiques de libération du principe actif à partir des formulations en silicone ont été 
réalisées dans de la périlymphe artificielle (solution aqueuse contenant : 1,2 mmol de chlorure 
de calcium dihydraté, 2mmol de sulfate de magnesium tétrahydraté, 2,7 mmol de chlorure de 
potassium, 145 mmol de chlorure de sodium et 5 mmol de HEPES). L’analyse du principe 
actif a été réalisée par HPLC-UV.  
Films 
La libération du principe actif à partir des films a été réalisée dans de la périlymphe 
artificielle à 37 °C (80 tours/min). A des temps prédéfinis, 1 mL du milieu de libération a été 
prélevé puis remplacé par de la périlymphe artificielle fraîche. 
Cellule de diffusion 
Un film sans principe actif a été placé dans une cellule de diffusion horizontale pour 
suivre la diffusion de la dexaméthasone : Le compartiment donneur comportait une solution 
saturée en principe actif, le compartiment receveur était quant à lui rempli de tampon 
initialement exempt de principe actif. A des temps prédéfinis, 1 mL du milieu de libération 
était prélevé puis remplacé par de la périlymphe artificielle fraîche. 
Implants « Ear Cube » 
Des implants « Ear Cube » ont été placés dans un tube Eppendorf coupé à la moitié de sa 
hauteur. Un trou de 0,4 mm percé dans le fond du tube permettait d’imiter la situation in vivo 
(l’implant est destiné a être placé dans l’oreille moyenne et donc est en contact avec la 
périlymphe au travers d’un trou). Pour maintenir l’implant en place, ce-denier était fixé avec 
du silicone. Ce tube était fixé dans un deuxième tube intact rempli avec 100 µl de périlymphe 
artificielle. A des temps prédéfinis, tout le milieu de libération était prélevé puis remplacé par 
la périlymphe artificielle fraîche. 
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Implants se formant in situ 
Des implants se formant in situ ont été placés dans un tube Eppendorf coupé à la moitié 
de sa hauteur. Un trou de 0,35 mm percé dans le fond du tube permettait d’imiter la situation 
in vivo (l’implant est destiné à être placé dans l’oreille moyenne et donc est en contact avec la 
périlymphe au travers d’un trou). Pour maintenir l’implant en place, ce-denier était fixé avec 
du silicone. Ce tube était fixé dans un deuxième tube intact rempli avec 100 µl de périlymphe 
artificielle. A des temps prédéfinis, tout le milieu de libération était prélevé puis remplacé par 
la périlymphe artificielle fraîche. 
 
 Caractérisation physico-chimique 
SEM 
La morphologie interne des formulations a été caractérisées par Scanning Electron 
Microscopy (S-4000; Hitachi High-Technologies Europe, Krefeld, Germany). Pour ce faire, le 
silicone chargé en dexaméthasone était congelé dans de l’azote liquide et brisé en deux pour 
scanner le point de rupture de la matrice. 
DSC 
Des implants « Ear Cube » ont été caractérisés par Differential Scanning Calorimetry 
(DSC Q10, TA Instruments, Guyancourt, France). Les implants étaient coupés (pour éviter un 
bruit de fond généré par la géométrie inégale de l’implant) et placés dans une coupelle 
ouverte. La poudre de dexaméthasone était analysée en conséquence. Les échantillons étaient 
refroidis à -150 °C et chauffés à 280 °C (10 K/min). 
X-ray diffraction 
Les implants « Ear Cube » ont été analysés par X-ray diffraction (PANalytical, Almelo, 
Netherlands) en mode transmission sous rotation. Les implants étaient coupés et seulement les 
cubes étaient placés dans les capillaires pour être analysés. 
 
 Etudes in vivo 
Les études in vivo ont été réalisées par Mme Julie Sircoglou. 
Trois groupes de gerbilles étaient analysés : 
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 13 gerbilles recevaient des implants se formant in situ. Ils étaient sacrifiés 
20 min, 7 et 30 jours après l’implantation. 
 
 2 gerbilles recevaient plusieurs injections de solution de dexaméthasone 
(intra-tympanique) pour prouver la spécificité de l’anticorps 
anti-dexaméthasone. 
 
 2 gerbilles ne recevaient pas de traitement (contrôle négatif). 
 
Les implants étaient implantés à côte de l’étrier en faisant un trou de 0,35 mm sous 
anesthésie générale. La formulation contenait 5 % de polyéthylène glycol 400 et 10 % de 
dexaméthasone. 
Après avoir sacrifié des gerbilles, les cochlées étaient explantées et analysées par 
microscopie confocale à balayage laser. 
 
3. Résultats et discussion 
La mobilité de la dexaméthasone dans les films 
Dans un premier temps, de fins films de silicone chargés en principe actif (PA) ont été 
préparés et caractérisé in vitro. La libération à partir de ces films peut être ajustée en 
modifiant le type de silicone (ex : le type des chaînes latérales, degré de réticulation) ou en 
ajoutant différents quantités de PEG 400 ou 1000.  
Dans le cas du silicone liquide, l’ajout de PEG augmente la libération du principe actif.  
L’ajout de différents ratios de PEG a une plus grande influence sur la libération que la 
variation du poids moléculaire de PEG : 
 
(i) L’ajout d’une concentration plus élevée de PEG augmente la vitesse de 
libération. 
(ii) L’introduction de PEG de poids moléculaire plus élevé augmente la 
vitesse de libération. 
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La modélisation mathématique effectuée considère que la diffusion est le principal 
mécanisme de la libération du principe actif (solutions analytiques et numériques de la 2nde loi 
de diffusion de Fick) ainsi que la solubilité du principe actif (modèles prenant en compte 
l’effet des limites de solubilité du principe actif, les processus de dissolution contrôlés par 
diffusion, les effets de couche stationnaire). L’érosion, le gonflement et la dissolution du 
polymère peuvent être négligés car le polymère est insoluble et ne gonfle pratiquement pas 
dans l’eau. L’analyse mathématique est réalisée sur de fins films de silicone chargés en 
principe actif afin de déterminer rapidement le coefficient de diffusion du principe actif. 
Les coefficients de diffusion « apparents » ont été déterminés : pour MED-4011 ils 
varient de D = 5,51 ± 1,71 à 64,54 ± 0,64 x 10-14 cm2/s, de D = 7,59 ± 0,58 à 72,04 ± 17,96 x 
10-14 cm2/s pour le silicone MED-6015 et de D = 22,41 ± 0,16 à 232,41 ± 5,78 x 10-14 cm2/s 
pour MED-6755 (tous pour les films sans PEG et les films contenants 10 % PEG 1000). Une 
bonne concordance était observée entre les cinétiques déterminées expérimentalement et 
calculées théoriquement avec ou sans ajout de PEG. Cela indique que la libération est très 
probablement contrôlée par diffusion. Il faut noter que la matrice contient des cristaux de PA 
– ce qui n’est pas pris en compte dans l’équation utilisée. C’est pourquoi le terme coefficient 
de diffusion « apparent » est utilisé. 
Les coefficients de diffusion « apparents » calculés sont conformes aux tendances 
observées sur les courbes de libération : Le coefficient le plus élevé correspond au film 
contenant 10 % de PEG 1000. 
Les cinétiques de libération des films préparés avec le silicone pâteux augmentent 
également par ajout de l’agent hydrophile dans la matrice. Par contre, les courbes de 
libérations calculées théoriquement diffèrent énormément des courbes observées 
expérimentalement. Les courbes calculées concordent seulement pour les films sans PEG. 
Ceci est une indication que la libération dans les films chargés en PEG n’est pas seulement 
contrôlée par diffusion mais d’autres processus interviennent. 
La modélisation a également été effectuée sur différents types de silicone et pour 
modéliser la libération de dexaméthasone à partir des films chargés en 10 à 50 % de PA. 
Basé sur ces résultats expérimentaux, le coefficient de diffusion du principe actif a été 
utilisé pour prédire de manière quantitative l’effet de différents paramètres de formulation et 
de procédé sur les cinétiques de libération résultantes pour des extrudats. Ces prédictions 
permettraient de faciliter et surtout d’accélérer l’optimisation de tels implants. 
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Implant « Ear Cube » 
Deux types d’implants ont été préparés en se basant sur les systèmes les plus 
prometteurs. 
Le premier est l’implant miniaturisé « Ear Cube » ayant une forme prédéfinie avec un 
cube lié à un cylindre. Ce cylindre est en contact avec la périlymphe de l’oreille interne. 
L’administration sous forme d’implant est moins invasive comparé à un implant cochléaire 
« classique » mais une cochleostomie est néanmoins nécessaire. L’implant peut être fixé sur la 
platine de l’étrier ou sur la fenêtre ovale en utilisant un polymère, ex du silicone qui réticule 
vite, in vivo. 
Simlairement aux films présentés précédemment, l’implant paraît opaque et blanc en 
raison des cristaux de PA piégés dans la matrice. Les cristaux sont bien visibles sur les images 
SEM. 
La DSC et la diffraction des rayons X ont confirmés ces résultats : La courbe DSC des 
implants « Ear Cube » chargés en dexaméthasone analysés contient un pic correspondant au 
PA observé avec la poudre seule. La surface du pic confirme que presque tout le PA inséré 
dans la matrice est présent sous une forme cristalline. Les rayons X confirme ces résultats car 
la courbe de l’implant non-chargé ne présente pas de pics. Par contre, la courbe observée avec 
un implant chargé présente des pics de dexaméthasone. 
Des films chargés en dexaméthasone ont été préparés pour servir de modèle simplifié 
pendant le développement de l’implant. Encore une fois, la libération est modélisée en se 
basant sur une solution analytique de la 2nde loi de diffusion de Fick. 
Les courbes théoriques concordent avec les courbes observées expérimentalement. La 
libération de dexaméthasone était donc contrôlée par diffusion et les coefficients de diffusion 
« apparents » ont été calculés. 
Le transport de dexaméthasone à travers une membrane en silicone a été réalisé pour 
comparer le coefficient de diffusion calculé pour la cellule de diffusion avec les valeurs 
calculés pendant la libération de PA à partir des films chargés. Le coefficient de diffusion 
trouvé dans le silicone non-chargé est de 1,9 x 10 -9 cm2/s. Comparé aux valeurs des films 
chargés en PA (3,4 à 4,9 x 10-14 cm2/s), la valeur du silicone non-chargé est beaucoup plus 
haute. La différence peut s’expliquer par la solubilité limitée de la dexaméthasone dans la 
matrice et la faible quantité de l’eau présente dans les films. Pour prédire la libération de 
   RESUME 
105 
 
principe actif, le coefficient de diffusion « apparent » peut malgré tout être utilisé car l’impact 
sur les valeurs prédites pourrait peut-être être négligeable. Il faut considérer tous les facteurs 
qui influencent le système choisi. 
La libération à partir des implants « Ear Cube » a été prédite en utilisant deux modèles se 
basant sur les coefficients de diffusion « apparents » observés sur les films chargés : 
 
(i) Un modèle qui considère la libération du PA à partir d’un cylindre. 
 
(ii) Un modèle qui considère la libération seulement à partir d’un cercle en bas du 
cylindre. 
 
Les calculs faits en utilisant le modèle (i) résultent en plus hautes concentration prédites 
comparés au modèle (ii) qui prédit des plus faibles concentrations libérés par le cercle. Les 
deux modèles prédisent une libération très faible pendant les deux premiers mois de la 
libération : Seulement 0,06 à 1,45 %, ou 0,046 à 2,35 µg dexaméthasone sont libérés selon les 
deux modèles. La libération in vivo peut donc être contrôlée sur de très longues périodes. 
Les implants « Ear Cubes » ont été préparés en réalité et la libération comparée avec les 
valeurs prédites par les deux modèles. Presque tous les résultats sont situés entre les les 
cinétiques de libération prédites par les deux modèles. Il faut admettre que les implants 
libèrent la PA in vivo probablement pas seulement à travers le cylindre. Il est possible que la 
dexaméthasone soit libérée à partir du cube à travers la fenêtre ovale. Ce phénomène n’était 
pas simulé avec le setup utilisé. Par conséquent, il est fort probable que la libération in vivo 
soit plus élevée comparée aux tests in vitro. 
L’étude de gonflement sert à exclure le phénomène de changement de dimension qui peut 
être crucial pour la faisabilité in vivo : Un implant qui gonfle pourrait avoir des effets néfastes 
pour le patient, notamment douloureux. L’absence de gonflement a été confirmée pour une 
période d’au moins 60 jours. 
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Implant se formant in situ 
Le second implant est un implant se formant in situ qui s’adapte parfaitement à 
l’anatomie de l’oreille moyenne en réticulant directement dans l’oreille moyenne. Cet implant 
est en contact avec l’oreille interne par un orifice.  
In vitro, le filme chargé à 10 % de dexaméthasone et de 5 % de PEG 400, montre une 
libération contrôlée pendant au moins 30 jours. Encore une fois, la libération était contrôlée 
par diffusion car une solution analytique de la 2nde loi de diffusion de Fick montre des 
résultats en concordance avec les courbes de libération qui étaient observés in vitro. Le 
coefficient de diffusion « apparent » est de D = 1.2 x 10-11 cm2/s. 
La libération à partir de l’implant est continue pendant la période d’observation. Le taux 
de dexaméthasone libéré est très faible comparé à la libération à partir des films. Ce 
phénomène peut s’expliquer par la surface très petite de l’implant en contact avec la 
périlymphe artificielle. 
La microscopie confocale laser a été utilisée pour confirmer la présence des cristaux de 
dexaméthasone dans les films chargés en PA. 
In vivo, la dexaméthasone a été détectée dans la cochlée. En préservant la structure 
intégrale de la cochlée, l’architecture de la cochlée a pu être observée. Les acquisitions 
tridimensionnelles  permettent d’examiner les cellules de l’oreille interne sous plusieurs 
points de vue. 
Plusieurs témoins non-implantés ou chargés avec les différentes étapes de l’immuno-
marquage permettent de prouver la spécificité du marquage. 
Les cochlées, explantés après 20 min, 7 jours et 30 jours montrent toutes une 
fluorescence indiquant que la dexaméthasone est libérée dans l’oreille interne. Le PA peut 
être détecté déjà 20 min après implantation  jusqu’à au moins 30 jours avec une intensité 
maximale à 7 jours après implantation. 
Un zoom sur les cellules ciliées prouve que la dexaméthasone est absorbée par ces 
cellules – même sur la rangée des cellules ciliées interne le PA peut être détectée. 
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4. Conclusion 
Le traitement de la surdité et des autres maladies de l’oreille interne reste un challenge 
car l’étiologie de ces maladies reste dans la plupart des cas inconnue. Des thérapies ciblant un 
traitement local et contrôlé de la cochlée sont actuellement e cours de développement. Les 
difficultés majeures sont les dimensions très petites de la cochlée et la sensibilité des cellules 
ciliées envers les changements de pression. Un principe actif tel que la dexaméthasone peut 
être incorporé dans le polymère et libéré de manière prolongée et homogène dans la 
périlymphe. Ainsi, la dexaméthasone peut aider à prévenir l’inflammation et la perte de 
nombreuses cellules ciliées après l’opération. Pour cela, deux types d’implants miniaturisés 
ont été développés. 
Dans la première partie, des films chargés en dexaméthasone ont été préparés pour 
identifier différentes stratégies permettant d’ajuster les cinétiques de libération in vitro. Pour 
ce faire, différents types de silicones ont été testés de même que l’ajout d’un agent hydrophile, 
le PEG. Le taux et la masse moléculaire du PEG ont été variés. Ces différentes stratégies 
permettent d’atteindre une large gamme de cinétiques de libération. 
Ces résultats ont été utilisés pour optimiser la libération de dexaméthasone in vitro à 
partir des implants « Ear Cube ». Ces implants miniaturisés ont l’avantage d’avoir une forme 
prédéfinie qui permet aussi de prédire de manière quantitative la libération à partir du cylindre 
de l’implant inséré sur (ou à côté de) la fenêtre ovale. 
Le deuxième implant consiste d’un silicone liquide réticulant très vite quand les deux 
composés sont mélangés. De plus, la formulation se présente sous forme liquide, et est donc 
très facile à gérer par le chirurgien avant implantation. Un autre avantage est que cet implant 
prend la forme de l’oreille du patient, et  s’adapte donc parfaitement. La libération in vitro est 
prolongée pendant au moins 30 jours, ce qui est confirmé par des images de microscopie 
confocale à balaye laser. La dexaméthasone est détectée après 20 min jusqu’à au moins 30 
jours après l’implantation. 
Ainsi, les deux implants semblent prometteurs pour contrôler à long terme la libération 
de dexaméthasone directement dans l’oreille interne. A l’avenir, des études pour évaluer les 
effets des implants « Ear Cube » seront menées. De plus, ces systèmes pourraient être adaptés 
pour délivrer d’autres PA, ex μ la gentamicine, pour traiter d’autres maladies. 
   LIST OF PUBLICATIONS 
108 
 
List of Publications 
Research Articles 
 
Gehrke, M; Sircoglou, J; Gnansia, D; Tourrel, G; Lacante, E; Vincent, C; Siepmann, J; 
Siepmann, F (2016) Ear Cubes for Local Controlled Drug Delivery to the Inner Ear. Int. J. 
Pharm. Accepted 
 
Gehrke, M; Sircoglou, J; Vincent, C; Siepmann, J; Siepmann, F (2016) How to adjust 
dexamethasone mobility in silicone matrices: A quantitative treatment. Eur. J. Pharm. 
Biopharm. 100, 27-37. 
 
Sircoglou, J; Gehrke, M; Tardivel, M; Siepmann, F; Siepmann, J; Vincent, C (2015) 
Trans-Oval-Window Implants, A New Approach for Drug Delivery to the Inner Ear: 
Extended dexamethasone release from silicone-based implants. Otology & Neurotology, 
36(10), 1572-1579. 
 
Siepmann, J; Karrout, Y.; Gehrke, M; Penz, FK; Siepmann, F (2013) Predicting drug 
release from HPMC/lactose tablets. Int. J. Pharm. 441, 826-834. 
 
Oral Communications 
 
Siepmann, J; Gehrke, M; Sircoglou, J; Vincent, C; Siepmann, F (2014) Local Controlled 
Drug Delivery to the Inner Ear. 1st International AMPTEC Conference (Advanced Materials 
and Pharmaceutical Technologies), Lille, France. 
 
Gehrke, M; Vincent, C; Siepmann, J; Siepmann, F (2013) Adjustment of drug release of 
dexamethasone from cochlear implants. 7th Pharmaceutical Solid State Cluster Annual 
Meeting, Lille, France. 
 
Gehrke, M; Krenzlin, S; Vincent, C; Gnansia, D; Siepmann, F; Siepmann, J (2012) In 
silico simulation of cochlear implants loaded with dexamethasone. 6th Pharmaceutical Solid 
State Cluster Annual Meeting, Lisbon, Portugal.  
   LIST OF PUBLICATIONS 
109 
 
Poster Presentations 
 
Gehrke, M; Verin, J; Gnansia, D; Tourrel, G; Vincent, C; Siepmann, J; Siepmann, F 
(2016) Hybrid Ear Cubes for Controlled Dexamethasone Delivery to the Inner Ear. 10th World 
Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Glasgow, UK. 
 
Gehrke, M; Sircoglou, J; Gnansia, D; Tourrel, G; Vincent, C; Siepmann, J; Siepmann, F 
(2016) Ear Cubes: A New Approach for Local Controlled Drug Delivery to the Inner Ear. 10th 
World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 
Glasgow, UK. 
 
Sircoglou, J; Gehrke, M; Tardivel, M; Siepmann, F; Siepmann, J; Vincent, C (2016) In-
situ Forming Trans-Oval-Window Implants for Controlled Drug Delivery to the Inner Ear. 
10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 
Glasgow, UK. 
 
Siepmann, F; Karrout, Y; Gehrke, M; Penz, F; Siepmann, J (2015) Even in the Case of 
Freely Water-Soluble Drugs Limited Solubility Effects can Play a Major Role in the Control 
of Drug Release from HPMC Tablets. AAPS Annual Meeting and Exposition, Orlando, USA. 
 
Siepmann, F; Karrout, Y; Gehrke, M; Moussa, E; Penz, F; Siepmann, J (2015) 
Computer-Aided Design of Controlled Release HPMC:Lactose-based Tablets. AAPS Annual 
Meeting and Exposition, Orlando, USA. 
 
Gehrke, M; Sircoglou, J; Vincent, C; Siepmann, J; Siepmann, F (2015) Importance of 
diffusion and limited drug solubility in silicone matrices for cochlear implants. 1st European 
Conference on Pharmaceutics: Drug Delivery, Reims, France. 
 
Gehrke, M; Vincent, C; Siepmann, J; Siepmann, F (2014) How Dexamethasone release 
can be adjusted from silicone matrices. 1st International AMPTEC Conference (Advanced 
Materials and Pharmaceutical Technologies), Lille, France. 
 
   LIST OF PUBLICATIONS 
110 
 
Gehrke, M; Vincent, C; Siepmann, J; Siepmann, F (2014) How Dexamethasone release 
can be adjusted from silicone matrices. 9th World Meeting on Pharmaceutics, 
Biopharmaceutics and Pharmaceutical Technology, Lisbon, Portugal. 
 
Gehrke, M; Vincent, C; Siepmann, J; Siepmann, F (2013) How to adjust desired drug 
release kinetics from cochlear implants. 3rd Conference on Innovation in Drug Delivery: 
Advances in Local Drug Delivery, Pisa, Italy. 
 
Gehrke, M; Vincent, C; Siepmann, J; Siepmann, F (2013) How to adjust desired drug 
release kinetics from cochlear implants. Forum du Prim " Rencontres de la Chimie, de la 
Biologie et de la Physique ", Lille, France.  
 
Siepmann, F; Karrout, Y.; Gehrke, M; Penz, FK; Siepmann, J (2013) A simple 
mathematical model allowing for the prediction of drug release from HPMC/lactose-based 
controlled release matrix tablets. AAPS Annual Meeting and Exposition, San Antonio, USA. 
 
Gehrke, M; Krenzlin, S; Vincent, C; Gnansia, D; Siepmann, J; Siepmann, F (2012) In 
silico simulation of cochlear implants loaded with dexamethasone. 4ème réunion annuelle de 
l’ITS, Lille, France. 
 
Siepmann, F; Karrout, Y.; Gehrke, M; Penz, FK; Siepmann, J (2012) Modeling Drug 
Release From RetaLac® Tablets: Impact of Drug Solubility. AAPS Annual Meeting and 
Exposition, Chicago, USA. 
   CURRICULUM VITAE 
111 
 
Curriculum Vitae 
 
Name   Maria Gehrke 
Birth   November 19, 1985 in Berlin, Germany 
Nationality  German 
 
Career 
 
Since 2016 Post-Doc at the Université de Lille, France 
 
2012 - 2016 Ph.D. student at the Université de Lille, France 
Subjectμ “Controlled Release of Dexamethasone to the Inner Ear from 
silicone-based Implants” 
Supervisor: F. Siepmann, C. Vincent 
Laboratory: INSERM U1008 Controlled Drug Delivery Systems and 
Biomaterials 
 
2012  License to practice  in a Pharmacy 
 
2011  Internship at the Pharmacy Prisma-Apotheke, Berlin, Germany 
  
2010  Internship at the Université de Lille, France 
Subjectμ “Preparation and characterization of controlled release matrices” 
Supervisor: F. Siepmann, Y. Karrout 
Laboratory: INSERM U1008 Controlled Drug Delivery Systems and 
Biomaterials 
 
2005 - 2010 Pharmaceutical studies at the Ernst-Moritz-Arndt-Universität Greifswald, 
Germany 
 
2005  High School Diploma at the Oberschule an der Weide, Berlin, Germany 
  
   CURRICULUM VITAE 
112 
 
Voluntary internships 
 
2009  Coordinating Center for Clinical Studies (KKS Charité), Berlin, Germany 
 
2008  Hospital Pharmacy Charité, Berlin, Germany 
 
2006  Pharmacy Apotheke im Friedrichshain, Berlin, Germany 
  
  Hospital Pharmacy Vivantes Klinikum Neukölln, Berlin, Germany 
 
2004  Pharmacy Apotheke am Ostbahnhof, Berlin, Germany 
 
Hospital Pharmacy Vivantes Klinikum im Friedrichshain, Berlin, Germany 
 
Assistance in organizing Workshops and Symposia 
 
2nd APGI Poorly Soluble Drugs Workshop (Lille, France), 2014 – 150 participants 
 
7th Pharmaceutical Solid State Research Cluster Symposium (Lille, France) 2013 – 
200 participants 
 
2nd APGI Coating Workshop (Lille, France), 2013 – 150 participants 
 
Reviewer for scientific Journals 
 
International Journal of Pharmaceutics 
  
   CURRICULUM VITAE 
113 
 
Training of pharmaceutical and medical Students 
 
Michaël Risoud: Université de Lille, France  
Master student, ENT specialist (12 months) 
 
Jérémy Verin:  Université de Lille, France   
Research assistant (3 months) 
 
Coralie Lacheretz: Université de Lille, France   
Master student, dentist (12 months) 
 
Emmely Lacante:  Universiteit Gent, Belgium  
Master student, pharmacist (4 months) 
 
Sanja Puric:   Univerza V Ljubljani, Slovenia 
Master student, pharmacist (4 months) 
 
Julie Sircoglou:  Université de Lille, France 
Master student, ENT specialist (12 months) 
 
Pierre Stievenard:  Université de Lille, France 
Internship student (1 month) 
 
Guillaume Dedieu:  Université de Lille, France 
Internship student (0.5 months) 
 
Linguistic skills 
 
German (mother tongue) 
English and French (fluent in spoken and written) 
Latin 
